

INVESTMENT AGREEMENT

among

MSP Recovery, LLC,

each Acquired Company,

and

Hazel Holdings I LLC

dated as of

March 29, 2023

INVESTMENT AGREEMENT

This Investment Agreement (this “**Agreement**”), dated as of March 29, 2023, is entered into among (i) MSP Recovery, LLC a Florida limited liability company (“**Seller**”), (ii) each of the designated series of MSP Recovery Claims, Series LLC, Delaware limited liability company, set forth on Schedule 1.1(a) attached hereto (each an “**Acquired Company**”, and collectively the “**Acquired Companies**”), (iii) Hazel Holdings I LLC, a Delaware limited liability company (“**HHI**”) and (iv) for purposes of ARTICLES III, VII, and VIII only, Subrogation Holdings, LLC, a Delaware limited liability company (the “**Company**”), and Series 44-20-461 and Series 44-20-456, each a designated series of MSP Recovery Claims Series 44, LLC, Delaware limited liability company (“**Series Companies**”).

RECITALS

WHEREAS, Seller, in coordination with its Affiliates, including the Acquired Companies, is in the business of identifying Responsible Parties and recovering costs or claims paid by or on behalf of Assignors that contract with governmental healthcare programs (i.e., Medicare) to provide benefits to persons who are covered under such programs (i.e., Medicare insureds) or other third parties with respect to care, services or supplies (including medications, treatments or other procedures) provided by or on behalf of Assignors or other entities that assign to or hire Assignors to provide such care, services or supplies, where such Assignors were not or should not have been the Responsible Party for such care, services or supplies (the “**Business**”).

WHEREAS, Seller owns 100% of the issued and outstanding equity interests of each of the Acquired Companies (the “**Equity Interests**”).

WHEREAS, on the terms and subject to the conditions set forth herein, Seller wishes to sell to HHI, and HHI wishes to purchase from Seller, the Equity Interests.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE I **DEFINITIONS**

The following terms have the meanings specified or referred to in this ARTICLE I:

“**Acquired Companies**” has the meaning set forth in the preamble.

“**Action**” means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity.

“**Affiliate**” means, with respect to any Person, any other Person who, directly or indirectly (including through one or more intermediaries), controls, is controlled by, or is under common control with, such Person. For purposes of this definition, “control,” when used with respect to any specified Person, means the power, direct or indirect, to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities or partnership or other ownership interests, by contract or otherwise; and the terms “controlling” and “controlled” have correlative meanings. For purposes

of this Agreement, Seller and (prior to the Closing) the Acquired Companies are Affiliates of one another. For the avoidance of doubt, for purposes of this Agreement, following the Closing the Acquired Companies shall be deemed to be Affiliates of HHI.

“**Agreement**” has the meaning set forth in the preamble.

“**Assigned Claims**” means all Claims (a) owned by any Acquired Company prior to or as of the Closing Date and (b) specifically encompassed in, delineated by, and assigned pursuant to the terms of, the CCRA applicable to each Acquired Company by the respective Assignor, in each case prior to, as of or following the Closing Date.

“**Assignor**” means any Person who (a) is (i) a Medicare Advantage Organization or health maintenance organization (each, an “**MAO Assignor**”) or (ii) a management service organization, an independent physician association, a medical center, a hospital or other health care organization that is not subject to a downstream capitation agreement in respect of its Claims (each, a “**Non-MAO Assignor**”), (b) contracts with governmental healthcare programs to provide Medicare benefits to persons who are covered under such programs (i.e., Medicare insureds) and (c) has a statutory right to recover from a Responsible Party for conditional payments made for healthcare, services or supplies provided to such insureds.

“**Assignor Interest**” means an interest in all or any portion of the Recovery Proceeds to which an Assignor is contractually entitled under a CCRA applicable to the Acquired Companies.

“**Bad Act**” and “**Bad Acts**” have the meaning set forth in Section 7.05.

“**Breach Notice**” shall mean a written notice that is provided by one party to another party under this Agreement, whereby one party informs the other party that the other party is in breach of a material representation, warranty, covenant or obligation under this Agreement. The Breach Notice shall be provided at least ten (10) days prior to the commencement of the Cure Period.

“**Business**” has the meaning set forth in the recitals.

“**Business Associate Subcontractor Agreement**” means any agreement between Seller or any of its Affiliates with an Assignor relating to the handling of protected health information in respect of Assigned Claims under applicable Law.

“**Business Day**” means any day except Saturday, Sunday or any other day on which commercial banks located in Miami, Florida are authorized or required by Law to be closed for business.

“**Cano Claims**” means the Assigned Claims defined in that certain Assignment, dated March 26, 2023, by and between Series 17-03-569 (“**Series 17-03-569**”), a designated series of MSP Recovery Claims, Series LLC, a Delaware limited liability company, and Series 23-03-1907, a designated series of MSP Recovery Claims, Series LLC, a Delaware limited liability company, which were assigned to Series 17-03-569 pursuant to the Amended and Restated Claims Recovery and Assignment Agreement, by and among Cano Health, LLC, Series 17-03-569, a designated series of MSP Recovery Claims, Series LLC, and Seller, dated December 31, 2021, as amended.

“**CanoHealth**” means Cano Health, LLC or one of its Affiliates.

“**CCRA**” means a health care claims costs recovery agreement between Seller, an Acquired Company, or any of their Affiliates, on the one hand, and an Assignor, on the other hand, or any similar

agreement, in each case, pursuant to which an Assignor assigned Claims to Seller, an Acquired Company, or any of their Affiliates that constitute Assigned Claims.

“Claim” means an Assignor’s right, title to, and/or interest in, any and all claims or potential claims, which the Assignor now has, or may have in the future (whether or not asserted), including all rights to causes of action and remedies against any Responsible Party at law or in equity. The term “Claim” includes but is not limited to: (i) claims arising under consumer protection statutes and laws; (ii) claims arising under the Medicare Act, 42 U.S.C. § 1395 *et seq.*, including but not limited to the Medicare and Medicare Advantage secondary payer statutes (42 U.S.C. § 1395y(b); 42 U.S.C. § 1395w-22(a)(4)), whether arising from contract, tort, statutory right, or otherwise, in connection with the conditional payment to providers of healthcare services or supplies, and (iii) all right, title, and/or interest in any recovery rights that may exist for any potential cause of action where “secondary payer” status is appropriate under 42 U.S.C. § 1395y(b), 42 C.F.R. § 411.20 *et seq.*, 42 U.S.C. § 1395w-22(a)(4) and 42 C.F.R. § 422.108, even where “secondary payer” status has not been established because liability is not yet proven as of the date that the Claim is identified or discovered, together with all receivables, general intangibles, payment intangibles, and other rights to payment now existing or hereafter arising and all products and proceeds of the foregoing. Notwithstanding the foregoing, the term “Claim” does not include any payments other than those payments made by Assignor pursuant to the Assignor’s (1) Medicare Advantage Organization agreement with the Center for Medicare & Medicaid Services or (2) downstream risk agreement with a Medicare Advantage Organization, as a management services organization, independent practice association, or other entity. The term “Claim” also does not include any potential claims or recoveries other than as expressly defined and limited by this definition for Claim, and notwithstanding anything to the contrary herein, as it relates to Assigned Claims, the term “Claims” shall be limited to the definition of same in the CCRA applicable to such Assigned Claims.

“Claims Data” has the meaning set forth in Section 5.08.

“Closing Date Purchase Price” has the meaning set forth in Section 2.02.

“Company” has the meaning set forth in the preamble.

“Company Indemnitees” has the meaning set forth in Section 7.02(a).

“Confidential Information” has the meaning set forth in Section 5.03.

“Confirmation Agent” means, as of the Closing Date, Crowe LLP, with a registered address of One Mid America Plaza, Suite 700, Oak Brook Terrace, IL 60181, United States, or such other confirmation agent as may subsequently be engaged by HHI from time to time in its sole discretion with respect to the valuation of Assigned Claims.

“Cure Period” shall mean, with respect to any breach which the parties agree is capable of being cured, thirty (30) calendar days. Except with respect to breaches that cannot be cured, a party shall have an opportunity to cure such breach during such Cure Period. With respect to breaches that cannot be cured, there shall be no Cure Period. For the avoidance of doubt, the Cure Period shall not apply to the parties’ covenants.

“Effective Date” has the meaning set forth in Section 2.03.

“Encumbrance” means any interest or equity (including any option or preemptive right), debt, claim, security interest, lien, encumbrance, participation, pledge, mortgage, retention agreement, hypothecation, right of third Persons, assessment, restriction, voting trust agreement, option, right of first

offer or refusal, proxy, title defect, rental, credit, factoring or conditional sale or other agreement on deferred terms and charge or other restriction or limitation of any nature whatsoever, whether arising under any contract or otherwise.

“**Equity Interests**” has the meaning set forth in the recitals.

“**Governmental Authority**” means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.

“**Governmental Order**” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority.

“**Gross Recovery Proceeds**” means, with respect to any Assigned Claim, the full gross proceeds received by HHI and/or the Acquired Companies following the Closing in respect of such Assigned Claim pursuant to the terms of the applicable CCRA, including compensation, interest, penalties and fees which may be paid with respect to such Assigned Claim (including any and all cash, securities, instruments or other property which may be paid or issued by defendants or third parties in litigation proceedings in satisfaction of such Assigned Claim).

“**HHI**” has the meaning set forth in the preamble.

“**Intellectual Property License Agreement**” means the Intellectual Property License Agreement dated as of the Closing Date between Seller, on the one hand and HHI, on the other.

“**Investor Preferred Amount**” means an aggregate amount equal to \$150,000,000.00.

“**Knowledge**” (or similar language) shall mean the knowledge of the John Ruiz and Frank Quesada and/or the principals, officers and managers of Seller and each Acquired Company, with the assumption that John Ruiz and Frank Quesada and/or such principals, officers and managers shall have made reasonable and diligent inquiry.

“**Law**” means any (a) constitutions, treaties, statutes, laws (including the common law), rules, regulations, decrees, ordinances, codes, proclamations, declarations or orders of any Governmental Authority; (b) any consents or approvals of any Governmental Authority; and (c) any orders, decisions, advisory or interpretative opinions, injunctions, judgments, awards, decrees of, or agreements with, any Governmental Authority; and (d) any orders, decisions, advisory or interpretative opinions, injunctions, judgments, awards, decrees of, or agreements with, any Governmental Authority.

“**Law Firm Contingency Fee**” means an amount equal to the product of (x) the Gross Recovery Proceeds in respect of the Assigned Claims multiplied by (y) 0.2 that is due to the MSP Law Firm and Milberg pursuant to the Legal Services Agreement.

“**Legal Services Agreement**” means the Legal Services Agreement, dated as of March 6, 2023, among MSP Law Firm, Milberg and the Company, pursuant to which MSP Recovery Law Firm and/or Milberg shall perform legal services for the Acquired Companies with respect to Assigned Claims.

“Losses” means losses, damages, liabilities, deficiencies, lost profits, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys’, consultants’ and experts’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; *provided, however,* that “Losses” shall not include punitive damages, except in the case of fraud or to the extent actually awarded to a Governmental Authority or other third party.

“**MAO Assignor**” has the meaning set forth in the definition of “Assignor” in this Article I.

“**Material Adverse Effect**” means any event, occurrence, fact, condition or change that is, or could reasonably be expected to become, individually or in the aggregate, materially adverse to the Acquired Companies or the recoverability of the Assigned Claims.

“**Medicare Advantage Organization**” means a company that has a contract with the Center for Medicare & Medicaid Services to provide Medicare Advantage plans and benefits to individuals.

“**Milberg**” means Milberg Coleman Bryson Phillips Grossman, LLC.

“**MSP Consideration**” means (i) the Closing Date Purchase Price, *plus* (ii) the Recovery Proceeds Payments pursuant to Section 2.04 hereof.

“**MSP Funnel Calculations**” means the data and calculations prepared by Seller and independently verified by the Confirmation Agent relating to potential Assigned Claims, provided to HHI prior to the date hereof, and set forth in **Exhibit B** attached hereto. Following the date hereof, the MSP Funnel Calculations may be updated from time to time (subject to examination by the Confirmation Agent) to reflect (a) any potential additional Assigned Claims which were not yet identified prior to the date hereof, or (b) other updates to data and calculations for purposes of valuation of any such Claims.

“**MSP Law Firm**” means La Ley con John H. Ruiz, d/b/a MSP Recovery Law Firm, a Florida corporation and MSP Law Firm, a Florida PLLC,

“**MSP Recovery**” means Seller and any of its Affiliates that provide Claims recovery services.

“**New Claims Purchase Agreement**” means that certain membership interest purchase agreement entered into among HHI, the Acquired Companies, and the Seller, substantially in the form attached hereto as **Exhibit A**.

“**Non-MAO Assignor**” has the meaning set forth in the definition of “Assignor” in this Article I.

“**Paid Amount**” means, with respect to an Assigned Claim, the amount that an Assignor has indicated as the “paid amount” for such Assigned Claim in the Claims Data provided by the Assignor to MSP Recovery pursuant to a CCRA, and which amount is set forth in the MSP Funnel Calculations as the “Paid Amount” and confirmed by the Confirmation Agent. If the Claims Data provided by the Assignor with respect to such Assigned Claim show a paid amount value of zero or otherwise refer to “encounter data” under a capitation agreement, then the Paid Amount for such Assigned Claim is determined by reference to the applicable Medicaid and Medicare rate tables. When these rate tables do not specifically identify a “Geo Zip”, the lowest possible rates must be used. Any Assigned Claims listed with “encounter data” or paid amount values of zero and not otherwise related to a capitation agreement will have a Paid Amount of zero.

“**Person**” means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association or other entity.

“Recovery Proceeds” means, with respect to any Assigned Claim, the full gross proceeds received by HHI and/or the Acquired Companies following the Closing in respect of such Assigned Claim pursuant to the terms of the applicable CCRA, including compensation, interest, penalties and fees which may be paid with respect to such Assigned Claim (including any and all cash, securities, instruments or other property which may be paid or issued by defendants or third parties in litigation proceedings in satisfaction of such Assigned Claim), less the Law Firm Contingency Fee; it being understood that 100% of such proceeds under the applicable CCRA are due to HHI and/or the Acquired Companies. For the avoidance of doubt, Recovery Proceeds include the Assignor Interest.

“Recovery Proceeds Payment” has the meaning set forth in Section 2.04.

“Representative” means, with respect to any Person, any and all directors, officers, employees, consultants, financial advisors, counsel, accountants and other agents of such Person.

“Responsible Party” means an insurance carrier, employer, self-insured entity or other Person or entity which may be liable to reimburse an Assignor under Applicable Law, including but not limited to the secondary payer provisions of the Medicare statute, 42 U.S.C. § 1395y(b), 42 C.F.R. § 411.20 et seq., the Medicare Advantage statute, 42 U.S.C. § 1395w-22(a)(4), 42 C.F.R. § 422.108, or under any other theories of law or causes of action, for the provision of healthcare, services or supplies that have been conditionally paid for by the Assignor.

“Seller” has the meaning set forth in the preamble.

“Series Companies” has the meaning set forth in the preamble.

“Taxes” means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.

“Tax Return” means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

“Transaction Document” means (i) this Agreement, (ii) the New Claims Purchase Agreement, (iii) the Intellectual Property License Agreement and (iv) Business Associate Subcontractor Agreement.

ARTICLE II PURCHASE AND SALE; CLOSING

Section 2.01 Purchase of Equity Interests. In exchange for the MSP Consideration, on the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller shall sell, assign, transfer and deliver to HHI, and HHI shall purchase and accept from Seller, all of Seller’s rights, title and interest in the Equity Interests, free and clear of all Encumbrances.

Section 2.02 Purchase Price. The aggregate consideration for the Equity Interests shall be \$150,000,000.00 (“**Closing Date Purchase Price**”). HHI shall pay the Closing Date Purchase Price to Seller on the Closing Date by wire transfer of immediately available funds to an account designated in

writing by Seller no later than three (3) Business Days prior to the Closing Date. HHI shall pay the Recovery Proceeds Payments in accordance with Section 2.04.

Section 2.03 Closing. The consummation of the sale of the Equity Interests pursuant to this ARTICLE II (the “**Closing**”) shall be held virtually (via the exchange of executed documents and other deliverables by PDF or other means of electronic delivery), as promptly as practicable following, but in no event later than, three (3) Business Days after the date on which the last of the conditions set forth in ARTICLE VI (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at the Closing) to be satisfied or waived is so satisfied or waived, or by such other means and/or at such other place, time and date as HHI and Seller may mutually agree in writing. All documents delivered and actions taken at the Closing shall be deemed to have been delivered or taken simultaneously, and no such delivery or action shall be considered effective or complete unless or until all other such deliveries or actions are completed or waived in writing by the party against whom such waiver is sought to be enforced. The date on which the Closing is actually held is referred to herein as the “**Closing Date**.”

Section 2.04 Recovery Proceeds Payments Waterfall.

(a) Following the Closing Date, (i) with respect to the Recovery Proceeds received for Cano Claims by any Acquired Company, ninety seven and one half percent (97.5%) of such Recovery Proceeds shall be retained by HHI or its Affiliates, and (ii) with respect to all Recovery Proceeds received by any Acquired Company in respect of all other Assigned Claims, 100% of such Recovery Proceeds shall be retained by HHI or its Affiliates, in each case until such time as HHI or its Affiliates have actually received in the aggregate the Investor Preferred Amount.

(b) Following such time that HHI or its Affiliates have actually received in the aggregate the Investor Preferred Amount, HHI shall pay to Seller or its designated Affiliate on the first business day of each calendar quarter, sixty five percent (65%) of the Recovery Proceeds received by HHI or its Affiliates in respect of Assigned Claims during the preceding quarter, less the amount paid to CanoHealth pursuant to Section 2.04(c) (each, a “**Recovery Proceeds Payment**”, and together, the “**Recovery Proceeds Payments**”).

(c) Following the Closing Date, the Acquired Companies shall pay or cause to be paid to CanoHealth two and one half percent (2.5%) of the Recovery Proceeds with respect to the Cano Claims, in accordance with the terms of the CCRA with CanoHealth.

ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER AND THE ACQUIRED COMPANIES

Seller, each Acquired Company, the Company and the Series Companies, jointly and severally, represent and warrant to HHI that the statements contained in this ARTICLE III are true and correct as of the date hereof and as of the Closing Date as if made thereon.

Section 3.01 Organization. Each of Seller and each Acquired Company is a limited liability company, duly organized, validly existing and in good standing under the Laws of the State of Delaware with full power and authority to own and operate the properties and assets now owned, operated or leased by it and to carry on its business as currently conducted. Each Acquired Company is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the execution of any CCRA, and ownership or assignment of any Claims or the proceeds or the operation of its business as currently conducted makes such licensing or qualification necessary.

Section 3.02 Authorization. Each of Seller and each Acquired Company has all requisite power, authority and legal right to (a) execute, deliver and perform this Agreement and the other Transaction Documents to which it is a party, (b) carry out its obligations under this Agreement and any other Transaction Document to which it is a party, and (c) assign, transfer and convey, or cause the assignment, transfer and conveyance of, the Equity Interests, on the terms and subject to the conditions provided herein, and (d) assign, transfer and convey, or cause the assignment, transfer and conveyance of, the applicable CCRAs and associated Assigned Claims to the applicable Acquired Companies (to the extent not already executed by or held by such Acquired Company). The execution and delivery by each of Seller and each Acquired Company of this Agreement and any other Transaction Documents to which it is a party, the performance by each of Seller and each Acquired Company of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all requisite action on the part of Seller and each Acquired Company.

Section 3.03 No Conflicts. The execution, delivery and performance by each of Seller and each Acquired Company of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of formation, limited liability company agreement or other organizational or governing documents of Seller or any Acquired Company or any of their respective Affiliates; (b) conflict with or result in a violation or breach of any provision of any applicable Law or Governmental Order applicable to Seller or any Acquired Company or any of its assets or the Business; (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel, any material contract to which Seller or any Acquired Company or any of their respective Affiliates is a party or by which they are bound or to which they are subject (including any CCRAs); or (d) result in the creation or imposition of any Encumbrance, other than Encumbrances imposed under federal and state securities laws or imposed by the terms of the limited liability company agreements of any Acquired Company[, as more specifically set forth on Schedule 3.03 of the Disclosure Schedule]. No consent, approval, permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Seller or any Acquired Company in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.

Section 3.04 Capitalization.

(a) Schedule 3.04(a) of the Disclosure Schedule sets forth the authorized and outstanding units or percentage interest of the Equity Interests of each Acquired Company, the name of each Person that is the registered and beneficial owner of any such Equity Interests of each Acquired Company, and the number and class of such units or amount of percentage interest owned by such Person. All issued and outstanding Equity Interests of each Acquired Company were issued in compliance with applicable Law and are (i) duly authorized, validly issued, fully paid and non-assessable; (ii) not subject to any preemptive rights created by statute, the governing documents of such Person or any agreement to which such Person is a party or to which it is subject; and (iii) free of any Encumbrances other than Encumbrances imposed under federal and state securities laws or as set forth on Schedule 3.03 of the Disclosure Schedule.

(b) There are no preemptive or other outstanding rights, options, warrants, conversion rights, profits interests, stock appreciation rights, redemption rights, repurchase rights, agreements, arrangements or commitments of any character under which any Acquired Company is or may become obligated to issue or sell, or give any Person a right to subscribe for or acquire, or in any way dispose of, any equity interests, or any securities or obligations exercisable or exchangeable for or convertible into any

equity interests, of such Acquired Company, and no securities or obligations evidencing such rights are authorized, issued or outstanding.

(c) Seller is the record and beneficial owner of, and has good and valid title to, one hundred percent (100%) of the Equity Interests, free and clear of all Encumbrances other than Encumbrances imposed under federal and state securities laws. Upon the Closing, Buyer will own one hundred percent (100%) of the Equity Interests of each Acquired Company, free and clear of all Encumbrances other than Encumbrances imposed under federal and state securities laws.

Section 3.05 Marketable Title. Each Acquired Company has good and marketable title to all of its assets, including the interest and rights under any contract to which such entity is a party (including any CCAs and applicable Claims and Recovery Proceeds thereunder), free and clear of Encumbrances. Each Acquired Company has the full legal power and authority to enter into each CCRA, and each has duly and validly executed and delivered each CCRA, and each CCRA and the Assigned Claims are free and clear of Encumbrances.

Section 3.06 Paid Amounts. The Paid Amounts set forth in the MSP Funnel Calculation are true and correct in all respects as of the date of this Agreement, and, in the event such Paid Amounts are update prior to the Closing Date, such amounts shall be true and correct in all respects as of the Closing Date.

Section 3.07 Enforceability. There is no fact that would cause any CCRA related to an Assigned Claim, or the assignment of any Assigned Claim, to be invalidated or to be unenforceable.

Section 3.08 Standing. Each Assignor has suffered an injury-in-fact necessary to establish, with regard to each Assigned Claim, that each Acquired Company has valid legal standing to bring an action to recover damages in connection therewith.

Section 3.09 CCAs. Complete and correct copies of each CCRA applicable to the Assigned Claims (including all schedules, exhibits, modifications, amendments and supplements thereto and waivers thereunder) have been made available to HHI prior to the date hereof. Each Acquired Company has made or will make, when due, full payment of any and all amounts required to have been paid to the Assignors (a) under the CCAs applicable to the Assigned Claims and (b) otherwise with respect to any Assigned Claims, in each case, as of the date hereof and as of the Closing Date with respect to the Assigned Claims. No CCRA related to the Assigned Claims has been restricted, terminated or revoked by any party thereto or any successors or assigns. No party to any CCRA related to an Assigned Claim is in breach of or default under any contractual obligations under such CCRA, including without limitation, any contractual requirement to provide current claim information as requested by each Acquired Company, or to take certain actions related to data privacy and security. Each Acquired Company has made any and all required or advisable requests for claim information. No Assignor party to any CCRA has commenced any actions or law suits, sent written notice of its intent to file any actions or law suits, or otherwise made any claim to any portion of the Recovery Proceeds.

Section 3.10 Consents. Seller and each Acquired Company has obtained all consents, approvals and permits, and has provided all notices, required to transfer the membership interests of each Acquired Company to HHI, including any consents required under any CCRA, and to perform any and all obligations under the CCAs, and otherwise in connection with the operation of the Business as currently conducted.

Section 3.11 Set-off. Except for any Assignor Interest due to an Assignor as contemplated in the CCAs, and any other rights set forth in the CCAs, no Acquired Company has entered into any

arrangement that would provide for any set-off or offset against, counterclaim or defense affecting, reduction of, deduction from, or defense against any Recovery Proceeds or other amounts that are receivable or retainable by any Acquired Company for its own account under the CCRA. Except for any prior recoveries of Assigned Claims disclosed to HHI prior to the date hereof, there have been no recoveries against any Assigned Claims, or any other abridgement of recovery rights associated with same.

Section 3.12 Purchase Price. As of the date hereof, Seller and each Acquired Company has provided all relevant and material information regarding the value of the Assigned Claims to HHI and the Confirmation Agent. However, the parties agree that the value calculated pursuant to the MSP Funnel Calculations is not a guarantee of the collection of such value or any amounts with respect to the Assigned Claims.

Section 3.13 Compliance with Laws. Each of Seller, each Acquired Company are, and for the past six (6) years have been, in compliance in all material respects with applicable Law with respect to the conduct of the Business, their properties or assets, and none of Seller, any Acquired Company have received any notice or communication of any material non-compliance with any such applicable Law that has not been cured. Neither Seller nor any Acquired Company , within the past six (6) years, has entered into or been subject to any judgment, consent decree, compliance order or administrative order with respect to any aspect of the Business, affairs, properties or assets of such Person or received any request for information, notice, demand letter, administrative inquiry or formal or informal complaint or claim from any Governmental Authority with respect to any aspect of the Business, affairs, properties or assets of such Person other than ordinary course inquiries and correspondence from Governmental Authorities and judgments, decrees and orders entered in by the applicable court in Actions relating to the recovery of proceeds from the Claims.

Section 3.14 Operative Documents. All documents and information provided by Seller to HHI in connection with the transactions contemplated hereby are the current operative and complete versions of such documents and contain the most current and accurate information based on the documents in Seller's or its Affiliates' possession.

Section 3.15 No Other Operations or Liabilities. Each Acquired Company was formed solely for the purpose of engaging in the Business, and except for operations, liabilities and obligations relating solely to the Business and incurred in the ordinary course of business, no Acquired Company is party to any contract or arrangement, nor has any Acquired Company otherwise conducted any business or incurred any liability or obligation.

Section 3.16 No Other Consideration. Other than the MSP Consideration, no amounts are due or payable under this Agreement to Seller or any of its Affiliates.

Seller does not by this Article III represent or warrant the outcome of any Action related to any CCRA. Notwithstanding the foregoing, in the event that any CCRA is hereafter held by a Governmental Authority to have been, as of the date hereof or the Closing Date, invalid, void or unenforceable for any reason, such that Seller or any of its Affiliates is entitled to a refund of, or indemnification from an Assignor for, any amount paid pursuant to such CCRA, HHI shall be entitled to such refund or any other such indemnification consideration paid to Seller or any of its Affiliates in connection with the Assigned Claims associated with such invalid, void, or unenforceable CCRA.

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF HHI

HHI represents and warrants to Seller that the statements contained in this ARTICLE IV are true and correct as of the date hereof.

Section 4.01 Organization. HHI is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.

Section 4.02 Authorization. HHI has all requisite power, authority and legal right to (a) execute, deliver and perform this Agreement and the other Transaction Documents to which it is a party, and (b) carry out its obligations under this Agreement and any other Transaction Document to which it is a party. The execution and delivery by HHI of this Agreement and any other Transaction Documents to which it is a party, the performance by HHI of its obligations hereunder and thereunder and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all requisite action on the part of HHI.

Section 4.03 No Conflicts. The execution, delivery and performance by HHI of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of formation, limited liability company agreement or other organizational or governing documents of HHI; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to HHI; (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel, any material contract to which HHI is a party or by which HHI is bound. No consent, approval, permit, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to HHI in connection with the execution and delivery of this Agreement or any of the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.

ARTICLE V COVENANTS

Section 5.01 Conduct of Business. From the date hereof until the Closing Date, except as otherwise provided in this Agreement or consented to in writing by HHI, each Acquired Company shall (x) conduct the Business in the ordinary course consistent with past practice and (y) use reasonable best efforts to maintain and preserve intact its current Business organization and operations. Without limiting the foregoing, from the date hereof until the Closing Date or earlier termination of this Agreement, each Acquired Company shall:

- (a) continue in full force and effect without modification all insurance policies carried by such Acquired Company, except as required by applicable Law;
- (b) ensure performance of all of the obligations under all CCRAs applicable to the Assigned Claims, and Transaction Documents;
- (c) comply in all material respects with all Laws applicable to the conduct of the Business or the ownership of and interest in the Assigned Claims; and
- (d) take no action that would likely have a Material Adverse Effect.

Section 5.02 Notice of Certain Events.

(a) From the date hereof until the Closing Date or earlier termination of this Agreement, Seller and each Acquired Company shall promptly notify HHI in writing of:

(i) any fact, circumstance, event or action the existence, occurrence or taking of which (A) has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, or (B) has resulted in, or could reasonably be expected to result in, any representation or warranty made by Seller or any Acquired Company hereunder being untrue or incorrect when made or as of the Closing Date; (C) has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in Section 6.02 to be satisfied;

(ii) any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement or any Transaction Document;

(iii) any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this Agreement or any Transaction Document;

(iv) any Actions commenced or, to Seller's Knowledge, threatened that relate to the consummation of the transactions contemplated by this Agreement; *provided, however,* that HHI understands and accepts that the Assigned Claims are the subject of various Actions seeking recoveries thereon, and that there are pending, and there shall be in the future, counterclaims and defenses to such Actions; and

(v) any Claims acquired by any Acquired Company or an Affiliate thereof.

(b) HHI's receipt of information pursuant to this Section 5.02 shall not operate as a waiver or otherwise affect any representation, warranty or agreement made by Seller or any Acquired Company in this Agreement (including Section 7.02 and Section 8.01(b)).

Section 5.03 Confidentiality.

(a) Each party acknowledges that, in connection with the transactions contemplated by this Agreement, it will have access to and become acquainted with, trade secrets, proprietary information and confidential information belonging to the other party(ies) and its Affiliates that is not generally known to the public, including, but not limited to, this Agreement, the other Transaction Documents, and their respective terms and provisions, information concerning business plans, financial statements and other information provided pursuant to this Agreement, operating practices and methods, expansion plans, strategic plans, marketing plans, contracts, customer lists or other business documents that each party treats as confidential, in any format whatsoever (including oral, written, electronic or any other form or medium) (collectively, "**Confidential Information**"). In addition, each party acknowledges that: (i) the other party(ies) has invested, and continues to invest, substantial time, expense and specialized knowledge in developing its Confidential Information; (ii) the Confidential Information provides such party with a competitive advantage over others in the marketplace; and (iii) such party would be irreparably harmed if the Confidential Information were disclosed to competitors or made available to the public. Without limiting the applicability of any other agreement to which any party is subject, no party will, directly or indirectly, disclose or use, including, without limitation, use for personal, commercial or proprietary advantage or profit, any Confidential Information of which such party is or becomes aware. Each party in possession of Confidential Information must take all appropriate steps to safeguard such information and to protect it against disclosure, misuse, espionage, loss and theft. Notwithstanding the foregoing, nothing in this Section 5.03(a) shall prevent HHI from using such Confidential Information to purchase Claims.

(b) Nothing contained in Section 5.03(a) will prevent any party from disclosing Confidential Information: (i) upon the order of any court or administrative agency; (ii) upon the request or demand of any regulatory agency or Governmental Authority having jurisdiction over such party; (iii) to the extent compelled by legal process or required or requested pursuant to subpoena, interrogatories or other discovery requests; (iv) to the extent necessary in connection with the exercise of any remedy or perform its obligations hereunder; (v) to a court or other adjudicatory forum by either party; (vi) to the other party(ies); (vii) to such party's Representatives who, in the reasonable judgment of such party, need to know such Confidential Information and agree to be bound by the provisions of this Section 5.03 as if a party; or (viii) to any investor or potential investor in HHI. To the extent that either party desires (at its sole expense) to challenge compelled disclosure contemplated by clauses (i), (ii), or (iii), the other party(ies) shall reasonably cooperate and assist the challenging party in connection with such challenge.

(c) The restrictions of Section 5.03(a) will not apply to Confidential Information that: (i) is or becomes generally available to the public other than as a result of a disclosure by a party in violation of this Agreement; (ii) is or has been independently developed or conceived by the receiving party without use of Confidential Information; or (iii) becomes available to the receiving party or any of its Representatives on a non-confidential basis from a source other than the disclosing party or any of its respective Representatives, provided, that such source is not known by the receiving party to be bound by a confidentiality agreement regarding the disclosing party.

(d) The obligations of each party under this Section 5.03 will survive for two (2) years following the termination or expiration of this Agreement.

Section 5.04 Public Announcements. Unless otherwise required by applicable Law (based upon the reasonable advice of counsel), no party hereto shall make any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of the other party(ies), and the parties shall cooperate as to the timing and contents of any such announcement.

Section 5.05 Receivables. From and after the Closing Date, if Seller or any of its Affiliates receives or collects any funds relating to the recovery of any Assigned Claims, Seller or such Affiliate shall remit such funds to HHI within five (5) Business Days after its receipt thereof.

Section 5.06 Transfer Taxes. All transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the other Transaction Documents shall be borne and paid by Seller when due. Seller shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and HHI shall cooperate with respect thereto as necessary).

Section 5.07 Further Assurances. Following the Closing Date, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the other Transaction Documents.

Section 5.08 Claims Data. From the date hereof until the date on which all Recovery Proceeds with respect to the Assigned Claims have been received (the "**Applicable Period**"), the Seller and its Affiliates shall provide HHI with full access to data and information reasonably necessary for HHI's continued pursuit and recovery of the Assigned Claims ("**Claims Data**"). Such Claims Data shall include all information due to Seller, each Acquired Company or their respective Affiliates (or HHI) from Assignors

under the CCRAs and any data produced by Seller and its Affiliates in connection with the identification and analysis of potential recoveries associated with the Assigned Claims. Seller, on behalf of itself and its Affiliates, hereby agrees to exercise and enforce their respective rights under the CCRAs to cause the Assignor or its Affiliates to continue to make available all Claims Data to Seller and its Affiliates, and attorneys and law firms engaged in prosecuting or otherwise pursuing recoveries through the conclusion of all recovery efforts, in each case, pursuant to the terms of the CCRAs and any formal or informal processes or pattern or practice Seller and its Affiliates have established to maximize the information flow in respect of the Claims, including the accessing of the patient and other claims data in respect of the Claims directly from the United States' Department of Health and Human Services Centers for Medicare & Medicaid Services Medicare Data Communications Network (MDCN) portal and other similar or analogous portals and platforms and any other data collection processes that Seller and its Affiliates have utilized or may utilize in the future to prosecute Claims and maximize recoveries thereunder. In furtherance and not by way of limitation of the foregoing, Seller, on behalf of itself and its Affiliates, agrees to and acknowledges HHI's and its Affiliates' rights to exercise or enforce any of the remedies pursuant to agreements between Affiliates of Assignee and Seller and its Affiliates in respect of the Claims. To help avoid or resolve any dispute or disagreement concerning the availability of Claims Data in respect of the Claims, Seller and its Affiliates shall, and shall cause each applicable assignee to, exercise and enforce their respective rights under the CCRAs to pursue by formal action or informal arrangements to cause Assignor to make available to Seller and its Affiliates, and attorneys and law firms engaged in prosecuting or otherwise pursuing recoveries from or under the Claims, any underlying claims files or other data relating to such Claims Data, for any Claims, including in the event of the expiration or termination of the CCRAs, and/or any agreement in furtherance of such arrangements, in order to allow such attorneys or law firms to use such Claims Data and related data to pursue recovery of the Claims.

Section 5.09 MSP Funnel Calculations. In the event HHI makes a written request, as it may determine in its sole discretion, Seller and its Affiliates shall use their best efforts to cooperate with Confirmation Agent, at HHI's sole cost, in order for Confirmation Agent to review, examine and verify the final MSP Funnel Calculations provided to HHI at or prior to Closing, including by providing Confirmation Agent with any Claims Data or other information or access to personnel necessary or advisable to perform such review, examination and verification. Confirmation Agent shall perform its review, examination and verification within sixty (60) days of the Closing Date. If Confirmation Agent's review and examination fails to verify the MSP Funnel Calculations, whether with respect to one Claim or multiple Claims, which, individually or in the aggregate, were purported to have a value of at least \$858,857,097 , HHI shall have the right, but not the obligation, to rescind this Agreement in part or in full, in its sole discretion.

Section 5.10 Settlement of Claims. In the event that Seller, or any of its] Affiliates settle any aggregate set of Claims similar to the Assigned Claims with a Responsible Party that also is a Responsible Party with respect to any of the Assigned Claims, Seller covenants and agrees that it shall, and shall cause its Affiliates to, if instructed to do so by HHI, (i) include the Assigned Claims in such settlement, and (ii) distribute the Recovery Proceeds to HHI obtained in connection with such settlement pro rata among the contractual beneficiaries thereof in accordance with the value of Assigned Claims in proportion to the value of the aggregate set of claims being settled. The value of such Assigned Claims will be determined by the relevant MSP Funnel Calculations (as adjusted solely for the settling time period and for market share of the relevant Assignors) compared to the value of the overall MSP Funnel Calculations that are part of such settlement.

ARTICLE VI CONDITIONS TO CLOSING

Section 6.01 Conditions to Obligations of All Parties. The obligations of each party to consummate the purchase of the Equity Interests as contemplated by this Agreement shall be subject to the fulfillment, at or prior to the Closing Date, of each of the following conditions, each of which has been confirmed, or waived, in writing by HHI as of the Closing Date:

(a) no Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order which is in effect and has the effect of making the transactions contemplated by this Agreement illegal, otherwise restraining or prohibiting consummation of such transactions or causing any of the transactions contemplated hereunder to be rescinded following completion thereof; and

(b) no Action shall have been commenced against HHI, Seller or any Acquired Company or their Affiliates, which would prevent or delay the transactions contemplated by this Agreement. No injunction or restraining order shall have been issued by any Governmental Authority, and be in effect, which restrains or prohibits any transaction contemplated hereby.

Section 6.02 Conditions to Obligations of HHI. The obligations of HHI to consummate the acquisition of the Equity Interests shall be subject to the fulfillment of, or HHI's written waiver with respect to, the following conditions as of the Closing Date:

(a) the representations and warranties of Seller, the Acquired Companies and the Company contained in this Agreement, the other Transaction Documents and any certificate or other writing delivered pursuant hereto, shall be true and correct in all respects (in the case of any representation or warranty qualified by materiality or Material Adverse Effect) or in all material respects (in the case of any representation or warranty not qualified by materiality or Material Adverse Effect) as of the date hereof and as of the Closing Date;

(b) each of Seller and each Acquired Company shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date;

(c) Seller shall have delivered to HHI a certificate or certificates signed by the manager, secretary or other authorized officer of Seller certifying, in the name of and on behalf of Seller, satisfaction of the conditions set forth in Section 6.02(a) and (b) above; *provided* that no manager, secretary or other authorized officer of Seller assumes any personal liability or obligation in relation thereto except in the event of fraud or willful misrepresentation;

(d) HHI shall have completed, and shall be satisfied with, in its sole and absolute discretion, its due diligence review of the Business, Seller, the Acquired Companies, the CCAs and Acquired Claims;

(e) Seller shall have delivered to HHI (i) membership interest assignment instrument(s) with respect to the Equity Interests, duly executed by Seller for transfer to HHI; (ii) a properly executed certificate pursuant to Treasury Regulations Section 1.1445-2(b) certifying that Seller is not a foreign person within the meaning of Section 1445 of the Code; and (iii) good standing certificate of Seller and each Acquired Company as of a recent date from the Secretary of State of the state of Delaware; and (iv) such other documents as HHI may reasonably request for the purpose of facilitating the consummation of any of the transactions contemplated hereby;

(f) Seller shall have delivered to HHI duly executed counterparts to the Transaction Documents (other than this Agreement);

(g) Seller shall have delivered to HHI all documents necessary to evidence a valid chain-of-assignment for each CCRA (e.g., executed assignments);

(h) Seller shall have obtained and delivered to HHI all consents from Assignors necessary or requested by HHI in connection with the transactions contemplated by this Agreement;

(i) with respect to any Assigned Claims, including without limitation, any prospective Claims arising under a CCRA, Seller shall have requested all data and information to which Seller or its Affiliates is entitled pursuant to each such CCRA regarding such Assigned Claims;

(j) Seller shall have obtained and delivered waivers or other instruments in a form reasonably acceptable to HHI waiving any existing purchase rights (such as rights of first refusal, rights of first offer, etc.) held by any third party pursuant to an agreement to which Seller or any Affiliate (including any Acquired Company) is a party, and which may interfere with HHI's ability to acquire or transfer any Claims;

(k) any Encumbrance on any Assigned Claim shall be terminated on or prior to the Closing Date, and Seller shall have delivered documentation reasonably requested by HHI evidencing such termination, including without limitation a form UCC-3 (to the extent that any financing statement (UCC-1) is on file with respect to such Encumbrance);

(l) no CCRA or assignment of Assigned Claims by Assignors have been definitively held or deemed to be invalid, void or unenforceable for any reason. To the extent any CCRA or assignment of Assigned Claims has been held or deemed to be invalid, void or, unenforceable, whether appealable or non-appealable, Seller shall disclose the status of the relevant actions prior to the Closing Date; and

(m) the applicable parties thereto shall have executed and delivered the HHI Interest Purchase Agreement and the transactions contemplated thereunder shall have been consummated concurrently with the Closing.

These conditions do not serve to expand, modify or amend any representations or warranties made by Seller or the Acquired Companies in Article III, and the representations and warranties of said parties are limited to those made by each party in Article III.

ARTICLE VII INDEMNIFICATION

Section 7.01 Survival. Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing Date and shall remain in full force and effect for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus sixty (60) days. All covenants and agreements of the parties contained herein shall survive the Closing Date indefinitely or for the period explicitly specified therein. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation or warranty or covenant and such claims shall survive until finally resolved.

Section 7.02 Indemnification By Seller.

(a) Subject to the other terms and conditions of this ARTICLE VII and the Breach Notice and Cure Period, Seller, the Company, and the Series Companies shall indemnify and defend each of HHI and its Affiliates and their respective Representatives (collectively, the “**Company Indemnitees**”) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses, incurred or sustained by, or imposed upon, the Company Indemnitees based upon, arising out of, with respect to or by reason of:

(i) any inaccuracy in or breach of any of the representations or warranties of Seller, the Company, the Series Companies or the Acquired Companies contained in this Agreement, the other Transaction Documents or in any certificate or instrument delivered by or on behalf of Seller or its Affiliates pursuant to this Agreement;

(ii) any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller or the Acquired Companies or their Affiliates pursuant to this Agreement, the other Transaction Documents or any certificate or instrument delivered by or on behalf of such Person pursuant to this Agreement;

(iii) any third-party claim based upon, resulting from or arising out of any gross negligence, malfeasance, willful misconduct in connection with the conduct of the Business, Seller the Acquired Companies or their respective Affiliates or the ownership of or rights or interests in the Assigned Claims existing or arising on or prior to the Closing Date; or

(iv) the invalidity of all or any portion of any CCRA related to any Assigned Claims, where such invalidity (A) causes the applicable Assigned Claims to become unenforceable or (B) creates a material adverse effect upon Seller’s, any Acquired Company’s and/or HHI’s rights and benefits pursuant to such CCRA or the Assigned Claims.

(b) Subject to the other terms and conditions of this ARTICLE VII and the Breach Notice and Cure Period, Seller, the Company, and the Series Companies shall indemnify and defend HHI against, and shall hold it harmless from and against, and shall pay and reimburse it for, any and all Losses incurred, sustained by, or imposed upon, HHI or any of its Affiliates based upon, arising out of, with respect to or by reason of HHI’s or its Affiliate’s inability to obtain Recovery Proceeds as a result of the application of any statutes of limitation relevant to any Assigned Claims. Notwithstanding the foregoing, to the extent a case applicable to Assigned Claims was ongoing or on appeal as of the Closing Date, and resulted in the need to re-file following subsequent dismissal, Seller’s indemnification obligations under this Section 7.02(b) shall still apply.

(c) Seller, the Company, and the Series Companies shall indemnify and defend HHI and its Affiliates against, and shall hold it harmless from and against, and shall pay and reimburse it for, any and all Losses incurred, sustained by, or imposed upon, HHI or its Affiliates based upon, arising out of, with respect to or by reason of a reduction in Seller’s or its Affiliate’s recovery of any Recovery Proceeds pursuant to a CCRA resulting from any Assignor’s contractual arrangements, including without limitation any downstream capitation arrangements, but only to the extent it affects the amount that Seller or any of its Affiliates would otherwise recover.

(d) HHI shall have the right to set-off, off-set or withhold all or a portion of any payment due or owing to Seller or any of its Affiliates pursuant to Section 2.04 against any payment due or owing to the Company Indemnitees pursuant to this Section 7.02.

Notwithstanding anything to the contrary above, the maximum indemnity obligation of Seller, the Company and the Series Companies under Section 7.02(a)(i) shall not exceed the MSP Consideration paid by HHI.

Section 7.03 Effect of Investigation. The representations, warranties and covenants of Seller and the Acquired Companies, and HHI's and the Company Indemnitees' right to indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of HHI or a Company Indemnitee (including by any of its Representatives) or the conclusions resulting from such investigation.

Section 7.04 Limitation on Certain Indemnity Obligations. Only to the extent that any indemnification obligations set forth in Section 7.02 arise from the acts or omissions of an Assignor and not Seller or any of its Affiliates, such obligations shall be capped at the greater of (a) any amounts actually recovered by Seller or its Affiliates from such Assignor (including legal fees and other expenses awarded); and (b) the MSP Consideration and the Recovery Proceeds Payments then paid by HHI to Seller for such Assigned Claims subject to indemnity.

Section 7.05 Non-Recourse. Notwithstanding anything in this Agreement to the contrary, any claim for indemnification or other damages based on or in respect of any liability of Seller, the Company, or any Series Company under this Agreement shall be subject to the Breach Notice and Cure Period; provided, however, that none of Seller, the Company, or any Series Company shall be exonerated or exculpated by this Section 7.05 in respect of fraud, malfeasance, or willful misconduct (each a “**Bad Act**” and collectively “**Bad Acts**”), and HHI may pursue damages against Seller, the Company, or any Series Company, but in no event shall the claim for damages against said parties for such Bad Acts under this Section 7.05 exceed the MSP Consideration paid by HHI.

ARTICLE VIII

MISCELLANEOUS

Section 8.01 Expenses. Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses. This provision does not pertain to any of the provisions that govern the sale and ultimate prosecution of the Assigned Claims negotiated herein. This provision is only intended to apply to expenses related to the transactions contemplated hereby.

Section 8.02 Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 8.02):

If to Seller or any Acquired Company prior to Closing: MSP Recovery, LLC
2701 S. Lejeune Rd., 10th Floor
Coral Gables, FL 33134
Attention: John H. Ruiz and Frank C. Quesada

Email: jruiz@msprecovery.com
fquesada@msprecovery.com

If to HHI or any Acquired Company after Closing: c/o Corporation Service Company, 251 Little Falls Drive, New Castle County, Wilmington, DE 19808
Facsimile: +442070749611
E-mail: msprecovery@hazelholdingsllc.com
Attention: Operations

with a copies to:

Prager Dreifuss, AG
E-mail: Daniel.Hayek@prager-dreifuss.com
Attention: Daniel Hayek

Holland & Knight LLP
31 West 52nd Street
New York, New York 10019
Attention: Waajid Siddiqui, Esq.
Email: waajid.siddiqui@hklaw.com

Section 8.03 Interpretation. For purposes of this Agreement, (a) the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; and (c) the words “herein,” “hereof,” “hereby,” “hereto” and “hereunder” refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Articles, Sections, Schedules and Exhibits mean the Articles and Sections of, and Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.

Section 8.04 Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

Section 8.05 Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.

Section 8.06 Entire Agreement. This Agreement and the other Transaction Documents constitute the sole and entire agreement of the parties hereto with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, or the Exhibits and Schedules hereto, the statements in the body of this Agreement will control.

Section 8.07 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. None of HHI or Seller may assign its rights or obligations hereunder without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed; *provided, however*, that prior to the Closing Date, HHI may, without the prior written consent of Seller, assign all or any portion of its rights under this Agreement to one or more of its Affiliates. No assignment shall relieve the assigning party of any of its obligations hereunder.

Section 8.08 No Third-party Beneficiaries. Except as provided in ARTICLE VII, this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

Section 8.09 Amendment and Modification; Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

Section 8.10 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.

(a) All issues and questions concerning the application, construction, validity, interpretation and enforcement of this Agreement will be governed by and construed in accordance with the internal laws of the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of New York.

(b) EACH PARTY HERETO HEREBY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

(c) Except as otherwise set forth in Section 8.11, each party hereby (i) irrevocably and unconditionally submits to the exclusive jurisdiction of the courts of the State of New York and any state appellate court therefrom within the State of New York, for purposes of any actions, suits or proceedings arising out of or relating to this Agreement, (ii) agrees not to commence any proceeding except in such courts and (iii) irrevocably waives, to the fullest extent permitted by Law, any objection which such party may now or hereafter have to the laying of the venue of any such court or that such proceeding has been brought in an inconvenient forum.

Section 8.11 Specific Performance. The parties agree that irreparable damage, for which monetary damages (even if available) would not be an adequate remedy, would occur if any provision of this Agreement were not performed in accordance with its specified terms or are otherwise breached by the parties hereto. Accordingly, the parties hereto acknowledge and agree that the parties shall be entitled to

an injunction, specific performance or other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof, in addition to any other remedy to which they are entitled at Law or in equity. Each of the parties hereto agrees that it shall not oppose the granting of an injunction, specific performance and/or other equitable relief on any basis, including the basis that any other party has an adequate remedy at Law or that any award of an injunction, specific performance and/or other equitable relief is not an appropriate remedy for any reason at Law or in equity. Any party hereto seeking: (a) an injunction or injunctions to prevent breaches of this Agreement; (b) to enforce specifically the terms and provisions of this Agreement; and/or (c) other equitable relief, shall not be required to show proof of actual damages or to provide any bond or other security in connection with any such remedy.

Section 8.12 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

Section 8.13 No Partnership. It is not the intention of the parties to create a partnership, joint venture, association, or other unincorporated organization or arrangement treated as a partnership for any purpose, including for U.S. federal income tax purposes. Further, neither this Agreement nor any Transaction Document shall be construed (i) as creating such a relationship or (ii) to treat any party to be the partner of any other party for any purpose, including for U.S. federal income tax purposes.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date hereof by their respective officers thereunto duly authorized.

HHI
Hazel Holdings I LLC

By: 

Name: Christopher Guth

Its: Authorized Attorney

By: 

Name: Friedrich Andreae


Its: Authorized Attorney

[remainder of page intentionally blank; signatures continue on following page]

[Signature Page to Investment Agreement]

SELLER

MSP Recovery, LLC

DocuSigned by:
By: 
Name: John H. Ruiz
Title: Authorized Representative

[remainder of page intentionally blank; signatures continue on following page]

ACQUIRED COMPANIES

MSP RECOVERY CLAIMS, SERIES LLC – SERIES 21-12-1644

By: MSP Recovery, LLC, its manager

DocuSigned by:

By: _____
Name: John H. Ruiz
Title: Authorized Representative

MSP RECOVERY CLAIMS, SERIES LLC – SERIES 23-03-1907

By: MSP Recovery LLC, its manager

DocuSigned by:

By: _____
Name: John H. Ruiz
Title: Authorized Representative

MSP RECOVERY CLAIMS, SERIES LLC – SERIES 21-06-1592

By: MSP Recovery, LLC, its manager

DocuSigned by:

By: _____
Name: John H. Ruiz
Title: Authorized Representative

[remainder of page intentionally blank; signatures continue on following page]

Solely for purposes of Articles III, VII, and VIII:

Subrogation Holdings, LLC

By:  DocuSigned by:
Name: John H. Ruiz
Title: Authorized Representative

**MSP RECOVERY CLAIMS SERIES 44, LLC
– SERIES 44-20-461**

By:  DocuSigned by:
Name: John H. Ruiz
Title: Authorized Representative

**MSP RECOVERY CLAIMS SERIES 44, LLC
– SERIES 44-20-456**

By:  DocuSigned by:
Name: John H. Ruiz
Title: Authorized Representative

[end of signatures]

EXHIBIT A
HHI INTEREST PURCHASE AGREEMENT(S)

HHI INTEREST MEMBERSHIP INTEREST PURCHASE AGREEMENT

This HHI Interest Membership Interest Purchase Agreement ("Agreement") is made and entered into as of March 29, 2023 (the "Effective Date") by and among MSP Recovery, LLC, d/b/a LifeWallet, a Florida limited liability company ("Buyer"), Hazel Holdings I LLC, a Delaware limited liability company ("Seller"), MSP Recovery Claims Series 44, LLC, a Delaware limited liability company (the "Company"), and MSP Recovery Holding Series 01, LLC, a Delaware limited liability company ("Series 01"). Buyer, Seller, the Company and Series 01 are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

RECITALS

WHEREAS, Seller is the sole member of the Company, and owns of record and beneficially one hundred percent (100%) of the membership interests of the Company (collectively, the "Purchased Interest");

WHEREAS, the Company owns of record and beneficially one hundred percent (100%) of the membership interests of the series companies listed on Exhibit A hereto (each, a "Subsidiary" and collectively, the "Subsidiaries");

WHEREAS, certain of the Parties are also party to that certain:

(a) Investment Agreement, dated as of October 23, 2020, by and among Buyer (as assignee of Series MRCS ("Series MRCS"), a designated series of MDA, Series LLC, a Delaware series limited liability company), Series 01 and Seller (as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms therein, the "Investment Agreement");

(b) Membership Interest Pledge Agreement, dated as of October 23, 2020, by and between Buyer (as assignee of Series MRCS) and Series 01 (as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms therein, the "Pledge Agreement"); and

(c) Intellectual Property License Agreement, dated as of October 23, 2020, by and between Buyer and Series 01 (as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms therein, the "License Agreement").

WHEREAS, the Parties desire for Seller to sell to Buyer, and Buyer to purchase from Seller, the Purchased Interest, on the terms and subject to the conditions set forth in this Agreement (the "Transaction").

AGREEMENT

NOW, THEREFORE, in reliance on the foregoing recitals, and for other good and valuable consideration, including, without limitation, the mutual representations, warranties, covenants and agreements set forth in this Agreement, the receipt and sufficiency of which hereby are acknowledged, the Parties hereto agree as follows:

ARTICLE 1 PURCHASE OF MEMBERSHIP INTEREST AND OTHER COVENANTS

(a) In accordance with the terms and conditions of this Agreement, the Parties hereby

agree that at the Closing (as defined below), Seller shall sell, transfer, assign, convey and deliver to Buyer, free and clear of all liens, encumbrances or claims, in each case, created by Seller, (solely in its capacity as equity holder of the Purchased Interests), and Buyer shall purchase and accept from Seller, the Purchased Interest in exchange for Three Hundred Ninety Million Dollars (\$390,000,000.00) (the “**Closing Payment**”) to be paid on the Closing Date. At the Closing, Buyer shall pay to Seller the Closing Payment, by wire transfer of immediately available funds, to the account specified by Seller. At the Closing, Seller shall deliver to Buyer a membership interest assignment instrument, duly executed by Seller for transfer of the Purchased Interest to Buyer, and such other documents as Buyer may reasonably request for the purpose of evidencing the consummation of any of the transactions contemplated hereby.

(b) Effective as of the Closing, (i) each of the Investment Agreement, the Pledge Agreement and the License Agreement shall terminate and shall be of no further force or effect, (ii) each Party hereby unconditionally and irrevocably releases, waives and forever discharges each other Party and each of its affiliates, members, successors, predecessors, and subsidiaries, and each of their respective directors, owners, members, shareholders, officers, agents, and employees from any and all causes of action, claims and damages, including attorneys’ fees, whether known or unknown, foreseen or unforeseen, presently asserted or otherwise arising through the Closing based upon, related to, or in connection with, the Investment Agreement, the Pledge Agreement and the License Agreement and the ownership and operation of the Company and its subsidiaries, and (iii) Series 01 hereby releases and forever discharges the Buyer from all obligations under the Pledge Agreement and agrees to (i) file a UCC-3 Termination Statement to terminate the UCC-1 Financing Statement on file in the State of Delaware with respect to the Pledge Interests (as defined in the Pledge Agreement), and deliver a stamped copy of such UCC-3 Termination Statement to Buyer, and (ii) execute and deliver such documentation prepared by Buyer as Buyer may reasonably request to evidence such release and discharge.

(c) All Parties acknowledge and agree that no Party, nor any affiliate or representative of any Party, has made any express or implied warranty, representation, assurance or other commitment with respect to the Purchased Interests, the Company, its business or its operations of any kind, including any warranty or representation of fitness for specific purpose, or as to the accuracy or completeness of any information regarding the Purchased Interests, the Company, its business or its operations, furnished or made available to Buyer or its representatives.

ARTICLE 2 THE CLOSING

The Parties confirm that the completion of the purchase and sale of the Purchased Interest (the “**Closing**”) shall take place through the exchange of electronic copies of original signatures of the documents and agreements contained herein on the Effective Date (the “**Closing Date**”). All transactions contemplated herein to occur on and as of the Closing Date (the “**Transactions**”) shall be deemed to have occurred simultaneously and to be effective as of 12:00 a.m. Eastern Time on the Closing Date.

ARTICLE 3 TAXES

All Parties agree that no Party, nor any affiliate or representative of any Party, has made any warranty or representation regarding the tax consequences of the Transaction. No Party shall be responsible or liable in any way for the tax consequences of the Transaction to the other Parties hereto. Each Party shall look solely to, and rely solely upon, such Party’s own tax advisors with respect to the tax consequences of the Transaction.

ARTICLE 4 CONFIDENTIALITY

The Parties understand and acknowledge that the terms of this Agreement are confidential and, except as required by law or any governmental authority, no Party shall provide such information to any third party without the prior written consent of the other Parties. Notwithstanding the foregoing, the Parties shall be permitted to disclose such information to a Party's attorneys, accountants, and other such professional advisors as necessary in the course of the completion of the Transaction, or to a court or other adjudicatory forum. This provision shall survive and shall remain a continuing obligation of the Parties hereto even after the completion of all obligations set forth herein.

ARTICLE 5 GENERAL PROVISIONS

6.1 Entire Agreement. This Agreement, including without limitation the recitals and exhibits hereto, which are hereby incorporated by reference, constitutes the entire agreement and understanding among the Parties with respect to the transfer of the Purchased Interest and is a final expression of their agreement, and no evidence or oral or other written promises shall be binding.

6.2 Governing Law; Arbitration; Jurisdiction.

(a) All issues and questions concerning the application, construction, validity, interpretation and enforcement of this Agreement will be governed by, and construed in accordance with, the internal laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Delaware.

(b) Any dispute, controversy or claim arising out of or in relation to this Agreement, including the validity, invalidity, breach or termination thereof, shall be resolved by arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers' Arbitration Institution (the "Rules") in force on the date on which the Notice of Arbitration (as defined in the Rules) is submitted in accordance with the Rules. The number of arbitrators shall be three (3) and shall be selected in accordance with the Rules, whereby each of Buyer and Seller shall designate one arbitrator, and the two appointed arbitrators shall designate the presiding arbitrator, in consultation with the respective parties. The seat of the arbitration shall be Paris, France; provided that that proceedings may be conducted remotely by video conference at the request of any Party, to the extent allowed under the Rules. The arbitral proceedings shall be conducted in English. The time-limit with respect to the designation of an arbitrator shall be fifteen (15) days, provided that the tribunal may extend or shorten this time limit if the circumstances so justify. Notwithstanding the foregoing, the parties may agree at any time to submit the dispute to mediation in accordance with the Swiss Rules of Commercial Mediation of the Swiss Chambers' Arbitration Institution.

6.3 Further Actions. Each of the Parties hereto agrees to use all reasonable efforts to take, or cause to be taken all actions and to do, or cause to be done, all things necessary, proper, or advisable to consummate and make effective the Transaction. If at any time, including but not limited to after the Effective Date, any further actions are necessary or desirable to carry out the purposes of this Agreement, the Parties shall use their reasonable efforts to take such actions.

6.4 Assignment. No Party shall assign its rights or obligations under this Agreement without the prior written consent of the other Parties. This Agreement shall be binding on the Parties and their respective legal successors and permitted assigns.

6.5 Amendments; Non-Waiver. This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each Party hereto. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving.

No waiver by any Party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

6.6 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[End of Text; Signature Page and Exhibit Follow]

IN WITNESS WHEREOF, the Parties hereto have signed this Agreement as of the Effective Date.

BUYER:

MSP Recovery, LLC

Name:

Title:

SELLER:

Hazel Holdings I LLC

Name:

Title:

COMPANY:

MSP Recovery Claims Series 44, LLC

Name:

Title:

SERIES 01:

MSP Recovery Holding Series 01, LLC

Name:

Title:

EXHIBIT A
SUBSIDIARIES

1. Series 44-20-934, a designated series of MSP Recovery Claims Series 44, LLC
2. Series 44-20-461, a designated series of MSP Recovery Claims Series 44, LLC
3. Series 44-20-388, a designated series of MSP Recovery Claims Series 44, LLC
4. Series 44-20-354, a designated series of MSP Recovery Claims Series 44, LLC
5. Series 44-20-634, a designated series of MSP Recovery Claims Series 44, LLC
6. Series 44-20-583, a designated series of MSP Recovery Claims Series 44, LLC
7. Series 44-20-456, a designated series of MSP Recovery Claims Series 44, LLC
8. Series 44-20-1262, a designated series of MSP Recovery Claims Series 44, LLC
9. Series 44-20-931, a designated series of MSP Recovery Claims Series 44, LLC

EXHIBIT B

MSP FUNNEL CALCULATIONS

HMO (V5.6) Distribution (Funnels and/or Layers)
MSP Client: AVDI-AVDI2
MSP CRD Batch: All
Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	23,853	786,811	\$69,604,911.21	\$364,476,823.76	\$77,274,629.39
AVDI	AVDI-AVDI-2	1: 1.2 P&C Accidents-F63	60	458	\$16,127.36	\$131,490.12	\$26,243.03
AVDI	AVDI-AVDI-2	2: 1.1 P&C Accidents-F64	14	55	\$44,661.23	\$59,414.34	\$46,404.43
AVDI	AVDI-AVDI-2	3: 1.5 P&C Accidents-F18	3,121	17,950	\$893,833.28	\$2,976,397.65	\$1,054,589.86
AVDI	AVDI-AVDI-2	4: 1.4 P&C Accidents-F19	739	10,340	\$1,749,204.27	\$14,372,234.81	\$1,863,657.30
AVDI	AVDI-AVDI-2	5: 1.3 P&C Accidents-F62	12,979	242,931	\$20,232,779.05	\$128,310,216.74	\$23,221,401.61
AVDI	AVDI-AVDI-2	6: 1.7 P&C Accidents-F16	1,031	4,965	\$280,110.98	\$2,355,298.05	\$333,118.97
AVDI	AVDI-AVDI-2	7: 1.6 P&C Accidents-F17	20,121	198,265	\$10,712,712.75	\$81,300,209.50	\$13,774,059.37
AVDI	AVDI-AVDI-2	8: 9.1 NDC Prograf-F40	178	2,695	\$235,911.84	\$278,254.28	\$235,911.11
AVDI	AVDI-AVDI-2	12: 11.1 EpiPen-F79	96	345	\$18,192.62	\$20,586.64	\$18,192.60
AVDI	AVDI-AVDI-2	13: 12.1 Generic Pharma-F92	24	50	\$1,033.79	\$1,358.02	\$1,033.79
AVDI	AVDI-AVDI-2	14: 12.2 Generic Pharma-F91	78	666	\$1,201.21	\$2,963.37	\$1,201.17
AVDI	AVDI-AVDI-2	15: 12.3 Generic Pharma-F90	1,340	11,988	\$169,105.23	\$169,615.52	\$169,101.40
AVDI	AVDI-AVDI-2	16: 12.4 Generic Pharma-F89	12	150	\$12,795.59	\$19,425.20	\$12,795.53
AVDI	AVDI-AVDI-2	17: 12.5 Generic Pharma-F88	31	97	\$725.50	\$1,258.21	\$725.50
AVDI	AVDI-AVDI-2	18: 12.6 Generic Pharma-F87	25	119	\$1,788.66	\$2,241.03	\$1,788.63
AVDI	AVDI-AVDI-2	19: 12.7 Generic Pharma-F86	3,581	29,733	\$333,080.19	\$367,679.56	\$333,071.05
AVDI	AVDI-AVDI-2	20: 12.8 Generic Pharma-F85	181	1,109	\$1,690.19	\$2,445.09	\$1,690.17
AVDI	AVDI-AVDI-2	21: 12.9 Generic Pharma-F80	303	3,102	\$41,007.20	\$65,991.98	\$41,006.07
AVDI	AVDI-AVDI-2	22: 12.10 Generic Pharma-F72	5	20	\$2,233.57	\$2,304.58	\$2,233.57
AVDI	AVDI-AVDI-2	23: 12.11 Generic Pharma-F68	189	1,357	\$1,892.42	\$7,960.44	\$1,892.31
AVDI	AVDI-AVDI-2	24: 12.12 Generic Pharma-F67	110	575	\$6,228.19	\$12,521.70	\$6,228.00
AVDI	AVDI-AVDI-2	26: 14.1 Insulin-F96	31	291	\$37,023.74	\$40,202.37	\$37,023.74
AVDI	AVDI-AVDI-2	27: 14.2 Insulin-F95	184	942	\$43,914.16	\$54,133.42	\$43,914.15
AVDI	AVDI-AVDI-2	28: 14.3 Insulin-F94	365	6,398	\$1,043,336.78	\$1,206,776.97	\$1,043,335.44
AVDI	AVDI-AVDI-2	29: 14.4 Insulin-F71	111	570	\$51,619.85	\$59,321.45	\$51,619.83
AVDI	AVDI-AVDI-2	30: 14.5 Insulin-F70	2	73	\$2,077.50	\$2,856.03	\$2,077.47
AVDI	AVDI-AVDI-2	31: 14.6 Insulin-F69	692	12,068	\$2,604,609.00	\$2,893,211.87	\$2,604,606.30
AVDI	AVDI-AVDI-2	32: 15.1 Aggrenox-F25	192	528	\$2,419.53	\$6,220.31	\$2,419.38
AVDI	AVDI-AVDI-2	33: 16.1 NDC Androgel-F27	228	3,170	\$126,183.99	\$167,475.40	\$126,183.42
AVDI	AVDI-AVDI-2	34: 17.1 Exjade Myfortic/Novartis-F78	5	44	\$4,814.33	\$5,330.76	\$4,814.31
AVDI	AVDI-AVDI-2	35: 19.5 DOJ Kickbacks Warn. Chil.-F157	1	9	\$1,686.84	\$2,366.84	\$1,686.84
AVDI	AVDI-AVDI-2	36: 19.4 DOJ Kickbacks Warn. Chil.-F158	2	11	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	37: 19.3 DOJ Kickbacks Warn. Chil.-F159	1	1	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	42: 20.1 NDC Actos-F81	2	12	\$284.27	\$384.27	\$284.27
AVDI	AVDI-AVDI-2	43: 21.1 Celgene-F97	39	1,425	\$7,105,856.39	\$7,448,147.75	\$7,105,857.67
AVDI	AVDI-AVDI-2	45: 22.1 Glucose Test Strips-F145	356	1,362	\$36,480.60	\$36,487.20	\$36,480.46
AVDI	AVDI-AVDI-2	46: 23.1 Namenda-F165	9	26	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	47: 24.1 Lidoderm-F193	368	2,567	\$31,942.59	\$37,975.49	\$31,942.45
AVDI	AVDI-AVDI-2	48: 24.2 Lidoderm-F192	10	32	\$1,332.39	\$1,692.49	\$1,332.39
AVDI	AVDI-AVDI-2	49: Clobetasol-F62	228	618	\$6,471.20	\$10,618.79	\$6,471.20
AVDI	AVDI-AVDI-2	50: Baclofen-F152	343	1,739	\$6,331.94	\$13,049.11	\$6,331.58
AVDI	AVDI-AVDI-2	51: Benazepril-F153	343	3,139	\$20,940.51	\$20,989.31	\$20,938.94
AVDI	AVDI-AVDI-2	52: Digoxin-F154	236	2,218	\$35,168.30	\$46,834.84	\$35,167.33
AVDI	AVDI-AVDI-2	53: Divalproex-F155	63	1,123	\$33,697.15	\$43,693.45	\$33,696.74
AVDI	AVDI-AVDI-2	54: Ursodiol-F156	32	315	\$34,500.49	\$38,049.13	\$34,500.38
AVDI	AVDI-AVDI-2	56: Aggrenox 2 NDC Generic-F266	27	419	\$47,232.37	\$56,388.67	\$47,232.24
AVDI	AVDI-AVDI-2	57: HP Acthar-f66	2	40	\$864,309.83	\$914,331.48	\$864,309.65
AVDI	AVDI-AVDI-2	58: Lipitor Pfizer-F75	10	113	\$6,126.79	\$7,500.56	\$6,126.79
AVDI	AVDI-AVDI-2	59: NDC Niaspan Brand-F208	1	25	\$8,989.99	\$9,024.45	\$8,989.97
AVDI	AVDI-AVDI-2	60: Restasis	580	5,046	\$1,040,009.35	\$1,104,467.87	\$1,040,008.59
AVDI	AVDI-AVDI-2	61: Zetia NDC-F250	4	5	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	62: Humira NDC Brand	36	682	\$1,274,802.10	\$1,303,186.93	\$1,274,802.60
AVDI	AVDI-AVDI-2	63: Evzio NDC	3	4	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	65: 2.Hip Replacement-192	2	4	\$2,696.21	\$22,511.25	\$2,696.21
AVDI	AVDI-AVDI-2	66: 2.Hip Replacement-193	5	12	\$9,587.51	\$78,518.25	\$12,515.67
AVDI	AVDI-AVDI-2	67: 2.Hip Replacement-194	7	105	\$3,645.31	\$80,240.55	\$3,969.51
AVDI	AVDI-AVDI-2	68: 2.Hip Replacement-195	4	202	\$22,346.21	\$298,784.49	\$23,700.37
AVDI	AVDI-AVDI-2	70: 2.Hip Replacement-197	2	4	\$979.76	\$10,075.00	\$3,303.39
AVDI	AVDI-AVDI-2	73: 2.Hip Replacement-200	11	94	\$2,096.46	\$58,425.65	\$2,163.27
AVDI	AVDI-AVDI-2	74: 2.Hip Replacement-201	7	79	\$5,840.22	\$23,411.43	\$6,830.89
AVDI	AVDI-AVDI-2	76: 2.Hip Replacement-203	3	4	\$836.64	\$3,586.00	\$859.43
AVDI	AVDI-AVDI-2	79: 2.Hip Replacement-207	1	1	\$94.38	\$478.00	\$94.38
AVDI	AVDI-AVDI-2	101: 2.Hip Replacement-230	12	30	\$29,137.74	\$140,851.25	\$37,922.21
AVDI	AVDI-AVDI-2	102: 2.Hip Replacement-231	8	107	\$29,312.33	\$173,610.21	\$29,489.36
AVDI	AVDI-AVDI-2	103: 2.Hip Replacement-232	7	53	\$2,371.34	\$11,040.01	\$2,371.34
AVDI	AVDI-AVDI-2	105: 2.Hip Replacement-235	1	1	\$8.08	\$32.00	\$8.08
AVDI	AVDI-AVDI-2	108: 2.Hip Replacement-238	15	174	\$9,092.50	\$53,317.76	\$9,297.62
AVDI	AVDI-AVDI-2	109: 2.Hip Replacement-239	9	31	\$1,035.57	\$2,474.05	\$1,035.57

HMO (V5.6) Distribution (Funnels and/or Layers)
MSP Client: AVDI-AVDI2
MSP CRD Batch: All
Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	23,853	786,811	\$69,604,911.21	\$364,476,823.76	\$77,274,629.39
AVDI	AVDI-AVDI-2	110: 2.Hip Replacement-240	1	2	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	111: 2.Hip Replacement-241	5	13	\$513.53	\$2,197.50	\$513.53
AVDI	AVDI-AVDI-2	118: 3.Pelvic Mesh-537	1	2	\$1,633.76	\$16,869.96	\$1,633.76
AVDI	AVDI-AVDI-2	120: 3.Pelvic Mesh-539	1	9	\$2,334.99	\$7,431.96	\$2,334.99
AVDI	AVDI-AVDI-2	123: 3.Pelvic Mesh-542	1	4	\$1,562.56	\$18,398.00	\$3,226.12
AVDI	AVDI-AVDI-2	126: 3.Pelvic Mesh-546	5	21	\$1,071.28	\$3,043.10	\$1,071.28
AVDI	AVDI-AVDI-2	130: 3.Pelvic Mesh-550	1	4	\$1,306.74	\$3,881.00	\$2,627.18
AVDI	AVDI-AVDI-2	132: 3.Pelvic Mesh-552	1	32	\$6,495.23	\$43,660.02	\$7,083.86
AVDI	AVDI-AVDI-2	151: 3.Pelvic Mesh-571	29	96	\$39,914.41	\$347,806.13	\$60,347.91
AVDI	AVDI-AVDI-2	153: 3.Pelvic Mesh-573	27	1,210	\$201,599.92	\$1,673,615.77	\$228,259.65
AVDI	AVDI-AVDI-2	155: 3.Pelvic Mesh-579	67	287	\$10,860.51	\$60,143.94	\$12,319.42
AVDI	AVDI-AVDI-2	156: 3.Pelvic Mesh-580	4	4	\$4,453.71	\$37,349.02	\$4,453.71
AVDI	AVDI-AVDI-2	169: 4.Granuflo-282	368	4,937	\$381,174.81	\$2,428,472.32	\$433,801.76
AVDI	AVDI-AVDI-2	171: 4.Granuflo-284	64	580	\$24,416.81	\$152,740.33	\$32,536.30
AVDI	AVDI-AVDI-2	173: 4.Granuflo-286	40	2,915	\$765,777.89	\$11,543,346.00	\$793,372.40
AVDI	AVDI-AVDI-2	209: 5.IVC Filter-347	100	1,825	\$505,664.65	\$2,901,723.18	\$544,286.39
AVDI	AVDI-AVDI-2	210: 6.Incretin-131	38	621	\$123,118.62	\$140,670.79	\$123,118.54
AVDI	AVDI-AVDI-2	211: 6.Incretin-132	20	760	\$212,429.00	\$1,638,716.55	\$219,848.08
AVDI	AVDI-AVDI-2	212: 6.Incretin-133	58	1,203	\$200,468.36	\$858,074.11	\$221,026.71
AVDI	AVDI-AVDI-2	214: 6.Incretin-135	1	26	\$10,426.48	\$37,592.64	\$10,426.48
AVDI	AVDI-AVDI-2	215: 6.Incretin-136	5	32	\$1,497.02	\$5,570.75	\$1,721.24
AVDI	AVDI-AVDI-2	216: 6.Incretin-137	982	18,040	\$3,894,709.28	\$4,408,077.69	\$3,894,707.59
AVDI	AVDI-AVDI-2	218: 6.Incretin-139	655	6,149	\$739,824.19	\$3,781,709.67	\$813,253.00
AVDI	AVDI-AVDI-2	226: 7.Taxotere-403	1	4	\$900.95	\$1,059.93	\$900.95
AVDI	AVDI-AVDI-2	229: 7.Taxotere-406	162	487	\$5,670.47	\$27,447.22	\$15,729.18
AVDI	AVDI-AVDI-2	234: 8.Meso/Asbestos-143	15	408	\$224,286.27	\$1,002,678.76	\$226,265.56
AVDI	AVDI-AVDI-2	235: 8.Meso/Asbestos-144	12	82	\$3,682.92	\$24,052.56	\$4,851.62
AVDI	AVDI-AVDI-2	237: 8.Meso/Asbestos-146	1	104	\$8,531.21	\$68,507.80	\$9,693.19
AVDI	AVDI-AVDI-2	239: 8.Meso/Asbestos-148	6	17	\$1,461.02	\$4,730.55	\$1,545.16
AVDI	AVDI-AVDI-2	245: 8.Meso/Asbestos-154	442	6,627	\$974,155.81	\$6,042,513.06	\$1,044,300.42
AVDI	AVDI-AVDI-2	306: Fluoroquinolone	468	3,725	\$638,001.42	\$5,838,284.68	\$680,416.66
AVDI	AVDI-AVDI-2	307: Fluoroquinolone	96	1,882	\$494,313.00	\$4,109,719.49	\$509,014.24
AVDI	AVDI-AVDI-2	310: Fluoroquinolone	782	15,195	\$3,992,390.56	\$30,746,213.50	\$4,111,547.68
AVDI	AVDI-AVDI-2	317: Opioids	677	18,548	\$622,764.63	\$754,256.73	\$622,760.50
AVDI	AVDI-AVDI-2	318: Opioids	427	2,385	\$37,423.95	\$356,846.71	\$63,006.04
AVDI	AVDI-AVDI-2	319: Opioids	4	6	\$0.00	\$1,930.00	\$0.00
AVDI	AVDI-AVDI-2	321: Opioids	6	9	\$237.56	\$1,674.00	\$487.77
AVDI	AVDI-AVDI-2	323: Opioids	4,736	35,364	\$179,782.78	\$300,393.22	\$179,775.35
AVDI	AVDI-AVDI-2	327: Opioids	5	6	\$115.37	\$1,083.83	\$115.37
AVDI	AVDI-AVDI-2	329: Opioids	19	133	\$1,420.21	\$8,007.28	\$2,244.89
AVDI	AVDI-AVDI-2	338: Viagra/Cialis	44	356	\$93,772.70	\$488,591.97	\$104,045.58
AVDI	AVDI-AVDI-2	343: Farxiga	4	12	\$6,024.25	\$6,318.25	\$6,024.25
AVDI	AVDI-AVDI-2	345: Farxiga	3	34	\$3,105.03	\$8,474.00	\$3,105.03
AVDI	AVDI-AVDI-2	347: Farxiga	165	2,492	\$440,652.13	\$499,158.31	\$440,651.76
AVDI	AVDI-AVDI-2	348: Farxiga	69	565	\$41,301.51	\$113,036.72	\$43,824.53
AVDI	AVDI-AVDI-2	350: Farxiga	8	99	\$26,039.88	\$117,769.26	\$26,491.36
AVDI	AVDI-AVDI-2	357: Invokana	4	29	\$2,033.13	\$7,204.51	\$2,033.13
AVDI	AVDI-AVDI-2	359: Invokana	36	212	\$16,222.00	\$17,278.09	\$16,222.00
AVDI	AVDI-AVDI-2	360: Invokana	48	289	\$44,268.72	\$245,784.01	\$44,743.96
AVDI	AVDI-AVDI-2	367: Proton Pump	78	810	\$106,618.07	\$126,316.92	\$106,617.71
AVDI	AVDI-AVDI-2	368: Proton Pump	752	19,086	\$451,153.91	\$9,494,886.00	\$570,236.60
AVDI	AVDI-AVDI-2	369: Proton Pump	79	636	\$64,008.60	\$548,264.56	\$69,053.64
AVDI	AVDI-AVDI-2	371: Proton Pump	141	1,571	\$182,591.57	\$222,144.08	\$182,591.10
AVDI	AVDI-AVDI-2	372: Proton Pump	35	165	\$17,392.87	\$166,380.10	\$19,307.93
AVDI	AVDI-AVDI-2	379: Valsartan NDC	43	680	\$13,946.11	\$15,425.79	\$13,945.91
AVDI	AVDI-AVDI-2	380: Valsartan NDC	49	1,838	\$405,407.41	\$2,247,790.96	\$453,531.47
AVDI	AVDI-AVDI-2	381: Valsartan NDC	31	1,213	\$133,124.04	\$789,920.91	\$145,605.46
AVDI	AVDI-AVDI-2	383: Valsartan NDC	986	11,143	\$245,242.70	\$247,500.12	\$245,237.92
AVDI	AVDI-AVDI-2	391: Benicar	10	108	\$14,243.33	\$16,894.16	\$14,243.26
AVDI	AVDI-AVDI-2	392: Benicar	247	2,209	\$189,276.98	\$1,441,187.75	\$216,404.08
AVDI	AVDI-AVDI-2	393: Benicar	183	914	\$43,829.49	\$217,074.63	\$52,655.28
AVDI	AVDI-AVDI-2	395: Benicar	3	3	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI-2	396: Benicar	22	57	\$1,963.88	\$8,441.44	\$2,698.41
AVDI	AVDI-AVDI-2	399: Benicar	6,133	44,472	\$3,264,198.42	\$19,800,089.25	\$3,711,470.41
AVDI	AVDI-AVDI-2	404: Testosterone	154	1,178	\$134,545.29	\$1,282,462.29	\$144,507.19

HMO (V5.6) Distribution (Funnels and/or Layers)
MSP Client: AVDI-AVDI3-2
MSP CRD Batch: All
Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	19,557	1,192,443	\$80,993,596.54	\$497,784,715.03	\$82,388,005.60
AVDI	AVDI-AVDI3-2	1: 1.2 P&C Accidents-F63	137	3,747	\$275,297.26	\$3,166,829.94	\$277,034.42
AVDI	AVDI-AVDI3-2	2: 1.1 P&C Accidents-F64	41	1,084	\$96,923.27	\$492,092.74	\$97,292.33
AVDI	AVDI-AVDI3-2	3: 1.5 P&C Accidents-F18	3,147	100,302	\$6,883,618.59	\$37,137,399.84	\$6,937,386.66
AVDI	AVDI-AVDI3-2	4: 1.4 P&C Accidents-F19	651	19,327	\$1,934,165.31	\$15,843,307.42	\$1,950,811.86
AVDI	AVDI-AVDI3-2	5: 1.3 P&C Accidents-F62	10,109	443,183	\$25,038,592.64	\$147,985,400.26	\$25,595,350.84
AVDI	AVDI-AVDI3-2	6: 1.7 P&C Accidents-F16	1,109	49,943	\$6,941,652.26	\$50,919,501.93	\$6,958,894.89
AVDI	AVDI-AVDI3-2	7: 1.6 P&C Accidents-F17	13,234	227,831	\$8,687,272.58	\$51,365,181.96	\$9,280,374.10
AVDI	AVDI-AVDI3-2	8: 9.1 NDC Prograf-F40	153	809	\$48,112.99	\$34,710.11	\$48,000.21
AVDI	AVDI-AVDI3-2	12: 11.1 EpiPen-F79	39	106	\$6,400.78	\$17,123.98	\$6,441.01
AVDI	AVDI-AVDI3-2	13: 12.1 Generic Pharma-F92	9	24	\$899.76	\$2,227.53	\$899.73
AVDI	AVDI-AVDI3-2	14: 12.2 Generic Pharma-F91	63	179	\$784.92	(\$13,047.18)	\$802.64
AVDI	AVDI-AVDI3-2	15: 12.3 Generic Pharma-F90	1,237	3,579	\$48,323.81	\$136,805.75	\$48,496.84
AVDI	AVDI-AVDI3-2	16: 12.4 Generic Pharma-F89	8	23	(\$2,967.45)	\$2,162.95	(\$2,967.48)
AVDI	AVDI-AVDI3-2	17: 12.5 Generic Pharma-F88	21	48	\$10,307.71	(\$430.69)	\$10,307.69
AVDI	AVDI-AVDI3-2	18: 12.6 Generic Pharma-F87	7	19	\$0.00	(\$2,434.20)	\$0.00
AVDI	AVDI-AVDI3-2	19: 12.7 Generic Pharma-F86	2,752	9,249	\$143,831.72	\$443,835.29	\$145,151.25
AVDI	AVDI-AVDI3-2	20: 12.8 Generic Pharma-F85	35	72	\$55.75	\$3,935.07	\$662.65
AVDI	AVDI-AVDI3-2	21: 12.9 Generic Pharma-F80	299	1,079	\$14,068.88	\$57,266.82	\$14,250.61
AVDI	AVDI-AVDI3-2	22: 12.10 Generic Pharma-F72	2	2	\$0.00	(\$6.75)	\$0.00
AVDI	AVDI-AVDI3-2	23: 12.11 Generic Pharma-F68	104	373	\$11,946.67	\$93,980.20	\$11,954.37
AVDI	AVDI-AVDI3-2	24: 12.12 Generic Pharma-F67	64	206	\$3,049.84	\$7,547.22	\$3,201.58
AVDI	AVDI-AVDI3-2	26: 14.1 Insulin-F96	14	86	\$13,422.15	\$14,805.35	\$13,422.10
AVDI	AVDI-AVDI3-2	27: 14.2 Insulin-F95	84	340	\$22,253.43	\$33,531.01	\$22,083.80
AVDI	AVDI-AVDI3-2	28: 14.3 Insulin-F94	408	3,061	\$397,775.97	\$466,765.14	\$398,294.58
AVDI	AVDI-AVDI3-2	29: 14.4 Insulin-F71	69	247	\$27,578.91	(\$23,478.43)	\$27,578.67
AVDI	AVDI-AVDI3-2	30: 14.5 Insulin-F70	5	31	\$266.03	(\$3,723.64)	\$266.02
AVDI	AVDI-AVDI3-2	31: 14.6 Insulin-F69	753	5,151	\$926,930.40	\$928,354.43	\$925,954.45
AVDI	AVDI-AVDI3-2	32: 15.1 Aggrenox-F25	95	220	(\$1,594.12)	\$5,665.72	(\$1,594.23)
AVDI	AVDI-AVDI3-2	33: 16.1 NDC Androgel-F27	281	1,189	\$50,567.61	\$179,238.47	\$49,882.93
AVDI	AVDI-AVDI3-2	34: 17.1 Exjade Myfortic/Novartis-F78	5	14	\$2,334.73	\$2,751.59	\$2,334.70
AVDI	AVDI-AVDI3-2	35: 19.5 DOJ Kickbacks Warn. Chil.-F157	6	18	\$1,097.68	\$1,706.86	\$1,105.71
AVDI	AVDI-AVDI3-2	43: 21.1 Celgene-F97	64	652	\$1,944,556.12	\$2,091,508.27	\$1,944,586.93
AVDI	AVDI-AVDI3-2	45: 22.1 Glucose Test Strips-F145	61	159	\$7,247.48	(\$1,386.64)	\$7,667.65
AVDI	AVDI-AVDI3-2	46: 23.1 Namenda-F165	5	14	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI3-2	47: 24.1 Lidoderm-F193	86	215	\$12,427.98	\$73,525.16	\$12,439.70
AVDI	AVDI-AVDI3-2	49: Clobetasol-F62	177	450	\$21,257.17	\$59,253.36	\$21,362.68
AVDI	AVDI-AVDI3-2	50: Baclofen-F152	239	702	\$13,552.20	\$43,215.50	\$13,811.41
AVDI	AVDI-AVDI3-2	51: Benazepril-F153	295	1,021	\$13,533.37	(\$26,347.23)	\$13,471.90
AVDI	AVDI-AVDI3-2	52: Digoxin-F154	145	564	\$15,308.43	(\$19,374.09)	\$15,243.09
AVDI	AVDI-AVDI3-2	53: Divalproex-F155	60	378	\$6,757.82	\$17,450.53	\$6,740.13
AVDI	AVDI-AVDI3-2	54: Ursodiol-F156	29	113	\$12,861.65	\$14,636.35	\$12,869.01
AVDI	AVDI-AVDI3-2	55: Aggrenox 2 NDC Brand-F265	1	1	\$26.79	\$41.21	\$26.79
AVDI	AVDI-AVDI3-2	56: Aggrenox 2 NDC Generic-F266	28	123	\$12,135.90	\$10,790.75	\$12,163.28
AVDI	AVDI-AVDI3-2	57: HP Acthar-F66	1	21	\$257,128.73	\$271,979.73	\$257,128.71
AVDI	AVDI-AVDI3-2	58: Lipitor Pfizer-F75	6	16	\$29.63	\$360.47	\$87.67
AVDI	AVDI-AVDI3-2	59: NDC Niaspan Brand-F208	2	13	\$4,387.18	\$6,176.78	\$4,387.16
AVDI	AVDI-AVDI3-2	60: Restasis	398	1,294	\$203,213.36	\$177,035.11	\$203,108.07
AVDI	AVDI-AVDI3-2	61: Zetia NDC-F250	2	2	\$43.00	(\$303.86)	\$43.00
AVDI	AVDI-AVDI3-2	62: Humira NDC Brand	68	289	\$346,885.77	\$388,471.20	\$346,986.28
AVDI	AVDI-AVDI3-2	65: 2.Hip Replacement-192	3	18	\$29,290.05	\$69,063.45	\$31,480.86
AVDI	AVDI-AVDI3-2	66: 2.Hip Replacement-193	2	4	\$3,920.42	\$39,838.00	\$3,920.42
AVDI	AVDI-AVDI3-2	67: 2.Hip Replacement-194	3	58	\$2,241.80	\$22,965.25	\$2,241.75
AVDI	AVDI-AVDI3-2	68: 2.Hip Replacement-195	1	8	\$0.00	\$0.00	(\$0.01)
AVDI	AVDI-AVDI3-2	70: 2.Hip Replacement-197	4	18	\$270.02	\$1,599.00	\$270.01
AVDI	AVDI-AVDI3-2	73: 2.Hip Replacement-200	3	14	\$1,458.31	\$3,675.82	\$1,458.28
AVDI	AVDI-AVDI3-2	74: 2.Hip Replacement-201	1	8	\$94.00	\$402.54	\$94.00
AVDI	AVDI-AVDI3-2	76: 2.Hip Replacement-203	1	1	\$44.50	\$200.00	\$44.50
AVDI	AVDI-AVDI3-2	79: 2.Hip Replacement-207	2	18	\$520.21	\$2,113.00	\$520.17
AVDI	AVDI-AVDI3-2	101: 2.Hip Replacement-230	7	63	\$10,893.00	\$61,082.59	\$10,892.91
AVDI	AVDI-AVDI3-2	102: 2.Hip Replacement-231	9	366	\$50,904.17	\$526,606.32	\$51,061.11
AVDI	AVDI-AVDI3-2	103: 2.Hip Replacement-232	6	108	\$4,352.30	\$39,771.99	\$4,359.27
AVDI	AVDI-AVDI3-2	105: 2.Hip Replacement-235	4	11	\$387.00	\$4,772.00	\$387.00
AVDI	AVDI-AVDI3-2	108: 2.Hip Replacement-238	5	564	\$30,171.52	\$169,042.54	\$30,194.19
AVDI	AVDI-AVDI3-2	109: 2.Hip Replacement-239	3	15	\$3,266.81	\$7,552.50	\$3,266.81
AVDI	AVDI-AVDI3-2	111: 2.Hip Replacement-241	3	16	\$1,388.12	\$9,479.00	\$1,410.88
AVDI	AVDI-AVDI3-2	117: 3.Pelvic Mesh-536	1	4	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI3-2	118: 3.Pelvic Mesh-537	1	7	\$0.00	\$2,190.00	\$971.94
AVDI	AVDI-AVDI3-2	120: 3.Pelvic Mesh-539	1	95	\$1,308.20	\$65,333.00	\$1,527.33
AVDI	AVDI-AVDI3-2	123: 3.Pelvic Mesh-542	1	2	\$1,558.72	\$12,543.00	\$1,558.72
AVDI	AVDI-AVDI3-2	126: 3.Pelvic Mesh-546	2	16	\$72.17	\$993.00	\$72.17
AVDI	AVDI-AVDI3-2	130: 3.Pelvic Mesh-550	1	3	\$388.00	\$2,487.00	\$388.00
AVDI	AVDI-AVDI3-2	132: 3.Pelvic Mesh-552	2	133	\$14,717.12	\$95,370.69	\$15,844.83
AVDI	AVDI-AVDI3-2	151: 3.Pelvic Mesh-571	23	130	\$23,137.06	\$199,781.42	\$23,484.80
AVDI	AVDI-AVDI3-2	153: 3.Pelvic Mesh-573	34	2,104	\$136,805.74	\$1,125,594.04	\$142,334.22
AVDI	AVDI-AVDI3-2	155: 3.Pelvic Mesh-579	16	226	\$5,422.22	\$28,352.15	\$6,053.55
AVDI	AVDI-AVDI3-2	156: 3.Pelvic Mesh-580	1	2	\$769.33	\$3,610.00	\$769.31
AVDI	AVDI-AVDI3-2	169: 4.Granuflo-282	174	7,208	\$981,039.85	\$11,603,752.72	\$984,483.78

HMO (V5.6) Distribution (Funnels and/or Layers)**MSP Client: AVDI-AVDI3-2****MSP CRD Batch: All****Date of Issue: March 15, 2023**

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	19,557	1,192,443	\$80,993,596.54	\$497,784,715.03	\$82,388,005.60
AVDI	AVDI-AVDI3-2	171: 4.Granuflo-284	116	4,185	\$1,029,390.61	\$6,191,309.13	\$1,031,552.70
AVDI	AVDI-AVDI3-2	173: 4.Granuflo-286	84	9,181	\$1,503,448.14	\$20,141,932.85	\$1,503,425.53
AVDI	AVDI-AVDI3-2	209: 5.IVC Filter-347	127	5,713	\$687,772.76	\$5,237,814.67	\$692,781.94
AVDI	AVDI-AVDI3-2	210: 6.Incretin-131	14	99	\$33,706.27	\$36,363.62	\$33,723.04
AVDI	AVDI-AVDI3-2	211: 6.Incretin-132	5	189	\$48,078.19	\$427,120.04	\$48,093.59
AVDI	AVDI-AVDI3-2	212: 6.Incretin-133	9	110	\$2,688.69	\$11,626.65	\$2,688.36
AVDI	AVDI-AVDI3-2	214: 6.Incretin-135	7	248	\$41,884.97	\$307,769.80	\$41,977.86
AVDI	AVDI-AVDI3-2	215: 6.Incretin-136	10	522	\$6,519.33	\$1,110,583.26	\$6,943.55
AVDI	AVDI-AVDI3-2	216: 6.Incretin-137	695	5,696	\$1,528,122.81	\$1,620,668.95	\$1,527,972.74
AVDI	AVDI-AVDI3-2	218: 6.Incretin-139	170	4,111	\$247,120.47	\$1,773,022.30	\$248,808.29
AVDI	AVDI-AVDI3-2	229: 7.Taxotere-406	37	163	\$5,026.19	\$21,577.04	\$5,184.94
AVDI	AVDI-AVDI3-2	234: 8.Meso/Asbestos-143	19	1,060	\$212,804.31	\$1,218,350.30	\$212,815.59
AVDI	AVDI-AVDI3-2	235: 8.Meso/Asbestos-144	9	260	\$13,034.33	\$43,327.56	\$13,252.04
AVDI	AVDI-AVDI3-2	237: 8.Meso/Asbestos-146	4	53	\$1,282.41	\$6,263.24	\$1,282.36
AVDI	AVDI-AVDI3-2	239: 8.Meso/Asbestos-148	4	69	\$469.04	\$7,461.43	\$535.13
AVDI	AVDI-AVDI3-2	306: Fluoroquinolone	53	1,238	\$53,839.63	\$531,735.31	\$54,076.21
AVDI	AVDI-AVDI3-2	307: Fluoroquinolone	13	124	\$6,346.81	\$31,910.76	\$6,346.63
AVDI	AVDI-AVDI3-2	310: Fluoroquinolone	128	2,965	\$272,491.14	\$2,370,812.22	\$277,089.35
AVDI	AVDI-AVDI3-2	317: Opioids	291	3,552	\$117,192.24	\$145,687.33	\$117,521.29
AVDI	AVDI-AVDI3-2	318: Opioids	80	2,064	\$155,773.18	\$791,158.82	\$157,506.82
AVDI	AVDI-AVDI3-2	319: Opioids	1	3	\$0.00	\$62.70	\$0.00
AVDI	AVDI-AVDI3-2	321: Opioids	78	1,673	\$31,766.24	\$289,950.97	\$32,883.80
AVDI	AVDI-AVDI3-2	322: Opioids	1	4	\$0.00	\$0.00	\$0.00
AVDI	AVDI-AVDI3-2	323: Opioids	2,303	12,115	\$172,116.79	\$301,402.34	\$173,720.28
AVDI	AVDI-AVDI3-2	327: Opioids	3	10	\$7.46	\$162.00	\$7.46
AVDI	AVDI-AVDI3-2	329: Opioids	57	907	\$26,738.10	\$159,766.66	\$27,260.36
AVDI	AVDI-AVDI3-2	347: Farxiga	156	1,165	\$261,155.90	\$277,398.94	\$261,154.88
AVDI	AVDI-AVDI3-2	348: Farxiga	37	401	\$35,553.40	\$154,582.34	\$35,612.19
AVDI	AVDI-AVDI3-2	350: Farxiga	19	195	\$51,943.01	\$179,055.87	\$51,970.47
AVDI	AVDI-AVDI3-2	359: Invokana	9	41	\$5,287.55	\$5,372.55	\$5,287.52
AVDI	AVDI-AVDI3-2	360: Invokana	2	11	\$342.59	\$606.00	\$357.55
AVDI	AVDI-AVDI3-2	362: Invokana	2	2	\$119.01	\$257.55	\$119.01
AVDI	AVDI-AVDI3-2	367: Proton Pump	22	171	\$16,257.39	\$19,166.57	\$16,257.24
AVDI	AVDI-AVDI3-2	368: Proton Pump	5	199	\$43,487.31	\$40,300.25	\$43,504.15
AVDI	AVDI-AVDI3-2	369: Proton Pump	1	3	\$85.96	\$184.00	\$85.95
AVDI	AVDI-AVDI3-2	371: Proton Pump	87	659	\$73,337.14	\$88,083.11	\$73,336.40
AVDI	AVDI-AVDI3-2	372: Proton Pump	2	33	\$3,832.64	\$36,958.00	\$3,832.64
AVDI	AVDI-AVDI3-2	379: Valsartan NDC	28	138	\$2,659.95	\$2,667.35	\$2,659.86
AVDI	AVDI-AVDI3-2	380: Valsartan NDC	14	328	\$35,631.37	\$229,125.04	\$35,673.27
AVDI	AVDI-AVDI3-2	381: Valsartan NDC	8	333	\$9,832.73	\$61,524.91	\$10,220.74
AVDI	AVDI-AVDI3-2	383: Valsartan NDC	764	3,066	\$78,094.98	\$80,459.61	\$78,092.69
AVDI	AVDI-AVDI3-2	391: Benicar	2	29	\$2,813.45	\$3,489.18	\$2,813.42
AVDI	AVDI-AVDI3-2	392: Benicar	1	17	\$448.00	\$1,940.00	\$637.67
AVDI	AVDI-AVDI3-2	393: Benicar	1	39	\$7,404.27	\$201,553.00	\$7,404.22
AVDI	AVDI-AVDI3-2	395: Benicar	2	15	\$895.42	\$993.02	\$895.40
AVDI	AVDI-AVDI3-2	399: Benicar	6,173	240,124	\$18,357,527.79	\$126,833,741.96	\$18,475,126.51
AVDI	AVDI-AVDI3-2	404: Testosterone	19	371	\$50,523.27	\$285,205.51	\$50,624.74

HMO (V5.6) Distribution (Funnels and/or Layers)
MSP Client: CANH-HUM6
MSP CRD Batch: All
Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	85,701	5,103,423	\$549,236,260.17	\$4,016,659,076.25	\$549,568,584.44
CANH	CANH-HUM6	1: 1.2 P&C Accidents-F63	694	5,834	\$401,900.64	\$2,319,720.91	\$402,898.47
CANH	CANH-HUM6	2: 1.1 P&C Accidents-F64	142	1,050	\$114,960.25	\$512,263.68	\$114,975.45
CANH	CANH-HUM6	3: 1.5 P&C Accidents-F18	13,517	179,639	\$13,343,023.21	\$68,973,149.56	\$13,357,205.57
CANH	CANH-HUM6	4: 1.4 P&C Accidents-F19	2,925	64,022	\$13,510,897.82	\$150,771,954.81	\$13,518,019.20
CANH	CANH-HUM6	5: 1.3 P&C Accidents-F62	52,303	1,863,238	\$146,107,778.18	\$1,326,860,071.05	\$146,285,934.21
CANH	CANH-HUM6	6: 1.7 P&C Accidents-F16	6,843	165,845	\$14,660,210.62	\$141,104,814.58	\$14,663,310.15
CANH	CANH-HUM6	7: 1.6 P&C Accidents-F17	54,633	723,475	\$77,560,274.49	\$603,321,512.95	\$77,636,010.87
CANH	CANH-HUM6	8: 9.1 NDC Prograf-F40	563	6,787	\$628,263.30	\$877,239.99	\$628,264.14
CANH	CANH-HUM6	12: 11.1 EpiPen-F79	179	453	\$69,632.44	\$75,180.72	\$69,632.44
CANH	CANH-HUM6	13: 12.1 Generic Pharma-F92	10	14	\$1,688.57	\$1,799.65	\$1,688.57
CANH	CANH-HUM6	14: 12.2 Generic Pharma-F91	265	1,826	\$20,299.63	\$24,704.58	\$20,305.91
CANH	CANH-HUM6	15: 12.3 Generic Pharma-F90	4,002	29,904	\$456,267.04	\$476,043.47	\$456,269.04
CANH	CANH-HUM6	16: 12.4 Generic Pharma-F89	9	81	\$15,727.02	\$15,734.82	\$15,727.02
CANH	CANH-HUM6	17: 12.5 Generic Pharma-F88	167	522	\$94,049.12	\$97,196.81	\$94,049.12
CANH	CANH-HUM6	18: 12.6 Generic Pharma-F87	272	932	\$357,541.76	\$374,822.06	\$357,541.76
CANH	CANH-HUM6	19: 12.7 Generic Pharma-F86	8,390	63,495	\$1,025,171.70	\$1,058,043.47	\$1,025,179.92
CANH	CANH-HUM6	20: 12.8 Generic Pharma-F85	6,819	14,399	\$265,572.36	\$275,515.91	\$265,572.36
CANH	CANH-HUM6	21: 12.9 Generic Pharma-F80	1,051	7,927	\$208,637.98	\$230,493.19	\$208,645.54
CANH	CANH-HUM6	22: 12.10 Generic Pharma-F72	2	8	\$0.00	\$0.00	\$0.00
CANH	CANH-HUM6	23: 12.11 Generic Pharma-F68	1,085	7,774	\$113,498.36	\$123,216.87	\$113,501.54
CANH	CANH-HUM6	24: 12.12 Generic Pharma-F67	301	1,041	\$46,962.62	\$56,389.48	\$46,962.62
CANH	CANH-HUM6	26: 14.1 Insulin-F96	583	2,381	\$787,278.55	\$838,392.14	\$787,278.55
CANH	CANH-HUM6	27: 14.2 Insulin-F95	3,924	40,329	\$17,434,207.74	\$17,869,752.42	\$17,434,207.74
CANH	CANH-HUM6	28: 14.3 Insulin-F94	1,148	12,758	\$6,307,149.88	\$6,480,472.02	\$6,307,149.88
CANH	CANH-HUM6	29: 14.4 Insulin-F71	1,003	4,172	\$1,023,379.64	\$1,087,330.16	\$1,023,379.64
CANH	CANH-HUM6	30: 14.5 Insulin-F70	2	15	\$2,155.29	\$2,305.29	\$2,155.29
CANH	CANH-HUM6	31: 14.6 Insulin-F69	3,038	32,824	\$21,089,453.77	\$21,508,389.24	\$21,089,453.77
CANH	CANH-HUM6	32: 15.1 Aggrenox-F25	890	2,472	\$43,429.45	\$47,751.42	\$43,429.45
CANH	CANH-HUM6	33: 16.1 NDC Androgel-F27	4,582	16,415	\$248,758.27	\$2,180,181.89	\$248,760.51
CANH	CANH-HUM6	34: 17.1 Exjade Myfortic/Novartis-F78	6	45	\$19,605.55	\$20,130.41	\$19,605.55
CANH	CANH-HUM6	36: 19.4 DOJ Kickbacks Warn. Chil.-F158	1	18	\$28,471.25	\$28,471.25	\$28,471.25
CANH	CANH-HUM6	42: 20.1 NDC Actos-F81	1	3	\$1,430.97	\$1,870.97	\$1,430.97
CANH	CANH-HUM6	43: 21.1 Celgene-F97	99	1,762	\$16,643,960.14	\$17,366,573.42	\$16,643,960.14
CANH	CANH-HUM6	44: 21.2 Celgene-F181	1	63	\$708,172.00	\$708,218.50	\$708,172.00
CANH	CANH-HUM6	45: 22.1 Glucose Test Strips-F145	80	498	\$15,116.43	\$15,162.77	\$15,116.43
CANH	CANH-HUM6	46: 23.1 Namenda-F165	3	16	\$2,400.18	\$2,464.48	\$2,400.18
CANH	CANH-HUM6	47: 24.1 Lidoderm-F193	577	2,227	\$136,723.87	\$155,972.15	\$136,723.87
CANH	CANH-HUM6	48: 24.2 Lidoderm-F192	3	33	\$24,055.31	\$24,086.41	\$24,055.31
CANH	CANH-HUM6	49: Clobetasol-F62	1,303	4,561	\$144,966.17	\$177,240.66	\$144,970.17
CANH	CANH-HUM6	50: Baclofen-F152	2,734	11,656	\$101,148.23	\$107,886.60	\$101,155.31
CANH	CANH-HUM6	51: Benazepril-F153	789	6,697	\$55,449.87	\$59,958.04	\$55,459.67
CANH	CANH-HUM6	52: Digoxin-F154	717	4,508	\$86,431.74	\$97,031.92	\$86,431.74
CANH	CANH-HUM6	53: Divalproex-F155	336	2,912	\$62,001.59	\$74,366.71	\$62,001.59
CANH	CANH-HUM6	54: Ursodiol-F156	30	287	\$27,117.92	\$28,480.01	\$27,117.92
CANH	CANH-HUM6	55: Aggrenox 2 NDC Brand-F265	2	17	\$7,030.29	\$7,030.29	\$7,030.29
CANH	CANH-HUM6	56: Aggrenox 2 NDC Generic-F266	7	19	\$2,466.28	\$3,112.53	\$2,466.28
CANH	CANH-HUM6	57: HP Acthar-f66	2	44	\$479,499.80	\$500,438.59	\$479,499.80
CANH	CANH-HUM6	58: Lipitor Pfizer-F75	9	43	\$21,562.91	\$23,466.53	\$21,562.91
CANH	CANH-HUM6	60: Restasis	1,583	10,346	\$5,352,681.87	\$5,476,034.21	\$5,352,681.87
CANH	CANH-HUM6	61: Zetia NDC-F250	7	45	\$2,574.99	\$2,574.99	\$2,574.99
CANH	CANH-HUM6	62: Humira NDC Brand	232	3,999	\$22,678,402.60	\$22,742,023.31	\$22,678,402.60
CANH	CANH-HUM6	65: 2.Hip Replacement-192	18	59	\$109,636.57	\$632,511.91	\$109,636.57
CANH	CANH-HUM6	66: 2.Hip Replacement-193	18	93	\$64,878.07	\$1,025,735.83	\$64,878.07
CANH	CANH-HUM6	67: 2.Hip Replacement-194	17	466	\$97,892.37	\$1,328,954.92	\$97,892.37
CANH	CANH-HUM6	68: 2.Hip Replacement-195	10	176	\$6,777.86	\$28,057.70	\$6,777.86
CANH	CANH-HUM6	70: 2.Hip Replacement-197	10	48	\$6,423.31	\$152,388.04	\$6,423.31
CANH	CANH-HUM6	71: 2.Hip Replacement-198	3	8	\$23,754.43	\$141,966.00	\$23,754.43
CANH	CANH-HUM6	73: 2.Hip Replacement-200	18	228	\$25,724.16	\$83,993.78	\$25,724.16
CANH	CANH-HUM6	74: 2.Hip Replacement-201	12	231	\$22,709.66	\$49,371.53	\$22,709.66
CANH	CANH-HUM6	76: 2.Hip Replacement-203	9	33	\$334.11	\$19,412.13	\$334.11
CANH	CANH-HUM6	78: 2.Hip Replacement-206	3	6	(\$567.20)	\$23,448.00	(\$567.20)
CANH	CANH-HUM6	79: 2.Hip Replacement-207	16	199	\$22,654.06	\$43,094.84	\$22,654.06
CANH	CANH-HUM6	80: 2.Hip Replacement-208	3	48	\$765.43	\$6,760.80	\$891.52
CANH	CANH-HUM6	82: 2.Hip Replacement-210	2	9	\$3,621.05	\$28,421.00	\$3,621.05
CANH	CANH-HUM6	85: 2.Hip Replacement-214	2	30	\$608.50	\$5,272.00	\$608.50
CANH	CANH-HUM6	101: 2.Hip Replacement-230	36	392	\$172,987.47	\$1,424,438.11	\$172,987.47
CANH	CANH-HUM6	102: 2.Hip Replacement-231	34	924	\$285,558.77	\$2,282,593.08	\$285,558.79
CANH	CANH-HUM6	103: 2.Hip Replacement-232	20	429	\$72,712.22	\$440,982.48	\$72,712.22
CANH	CANH-HUM6	105: 2.Hip Replacement-235	9	28	\$2,280.32	\$24,417.50	\$2,280.32
CANH	CANH-HUM6	108: 2.Hip Replacement-238	31	807	\$55,003.04	\$288,002.30	\$55,003.04
CANH	CANH-HUM6	109: 2.Hip Replacement-239	16	284	\$66,041.47	\$358,391.60	\$66,041.47
CANH	CANH-HUM6	111: 2.Hip Replacement-241	10	38	\$2,418.87	\$19,113.32	\$2,418.87
CANH	CANH-HUM6	117: 3.Pelvic Mesh-536	4	9	\$1,575.88	\$26,872.66	\$1,575.88
CANH	CANH-HUM6	118: 3.Pelvic Mesh-537	4	6	\$8,918.81	\$38,566.66	\$8,918.81
CANH	CANH-HUM6	120: 3.Pelvic Mesh-539	4	109	\$12,893.82	\$205,492.37	\$12,893.82
CANH	CANH-HUM6	123: 3.Pelvic Mesh-542	1	4	\$1,531.21	\$21,009.06	\$1,531.21
CANH	CANH-HUM6	126: 3.Pelvic Mesh-546	3	69	\$421.18	\$9,810.85	\$421.18
CANH	CANH-HUM6	130: 3.Pelvic Mesh-550	1	3	\$589.92	\$3,023.55	\$589.92

HMO (V5.6) Distribution (Funnels and/or Layers)

MSP Client: CANH-HUM6

MSP CRD Batch: All

Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	85,701	5,103,423	\$549,236,260.17	\$4,016,659,076.25	\$549,568,584.44
CANH	CANH-HUM6	132: 3.Pelvic Mesh-552	5	135	\$11,923.67	\$66,796.00	\$11,923.67
CANH	CANH-HUM6	151: 3.Pelvic Mesh-571	129	442	\$277,432.53	\$2,633,879.02	\$279,376.79
CANH	CANH-HUM6	153: 3.Pelvic Mesh-573	128	7,265	\$899,201.56	\$12,773,593.88	\$900,445.84
CANH	CANH-HUM6	155: 3.Pelvic Mesh-579	102	1,455	\$36,762.46	\$622,110.73	\$37,215.45
CANH	CANH-HUM6	156: 3.Pelvic Mesh-580	6	25	\$3,320.49	\$112,954.93	\$3,320.49
CANH	CANH-HUM6	169: 4.Granufllo-282	995	30,559	\$4,594,006.33	\$44,436,825.18	\$4,594,061.81
CANH	CANH-HUM6	171: 4.Granufllo-284	616	16,259	\$3,644,173.20	\$29,436,511.03	\$3,644,960.07
CANH	CANH-HUM6	173: 4.Granufllo-286	764	50,361	\$9,929,638.63	\$276,306,241.01	\$9,929,994.24
CANH	CANH-HUM6	209: 5.IVC Filter-347	509	14,952	\$5,963,506.96	\$47,357,030.30	\$5,963,930.97
CANH	CANH-HUM6	210: 6.Incretin-131	75	638	\$427,965.31	\$438,740.73	\$427,965.31
CANH	CANH-HUM6	211: 6.Incretin-132	58	2,664	\$658,466.32	\$4,500,009.36	\$658,506.59
CANH	CANH-HUM6	212: 6.Incretin-133	59	2,629	\$415,357.56	\$4,722,005.21	\$415,357.56
CANH	CANH-HUM6	214: 6.Incretin-135	25	713	\$84,942.96	\$398,810.39	\$84,942.96
CANH	CANH-HUM6	215: 6.Incretin-136	34	587	\$50,602.42	\$364,035.21	\$50,602.42
CANH	CANH-HUM6	216: 6.Incretin-137	4,081	41,995	\$26,988,403.56	\$27,922,467.17	\$26,988,403.56
CANH	CANH-HUM6	218: 6.Incretin-139	1,642	40,120	\$3,871,730.12	\$31,500,080.56	\$3,872,744.21
CANH	CANH-HUM6	226: 7.Taxotere-403	19	78	\$7,768.57	\$69,754.45	\$7,768.57
CANH	CANH-HUM6	229: 7.Taxotere-406	440	4,385	\$76,997.63	\$352,340.02	\$77,056.32
CANH	CANH-HUM6	234: 8.Meso/Asbestos-143	138	5,642	\$473,139.67	\$3,837,859.88	\$473,424.63
CANH	CANH-HUM6	235: 8.Meso/Asbestos-144	27	1,677	\$254,081.63	\$2,337,489.78	\$254,081.65
CANH	CANH-HUM6	237: 8.Meso/Asbestos-146	16	803	\$115,465.82	\$881,753.84	\$115,465.82
CANH	CANH-HUM6	239: 8.Meso/Asbestos-148	17	331	\$51,375.76	\$306,962.07	\$51,375.76
CANH	CANH-HUM6	306: Fluoroquinolone	553	13,579	\$1,085,669.62	\$9,120,997.97	\$1,085,730.96
CANH	CANH-HUM6	307: Fluoroquinolone	91	1,823	\$559,215.75	\$6,391,048.34	\$559,215.75
CANH	CANH-HUM6	309: Fluoroquinolone	1	3	\$328.26	\$332.16	\$328.26
CANH	CANH-HUM6	310: Fluoroquinolone	1,200	23,810	\$6,985,715.01	\$66,823,332.26	\$6,986,016.62
CANH	CANH-HUM6	317: Opioids	4,936	78,803	\$2,811,154.42	\$3,411,758.13	\$2,811,263.06
CANH	CANH-HUM6	318: Opioids	3,681	97,403	\$3,034,720.86	\$27,650,064.58	\$3,036,308.36
CANH	CANH-HUM6	319: Opioids	24	37	\$0.00	\$6,087.48	\$0.00
CANH	CANH-HUM6	321: Opioids	1,401	16,683	\$693,300.74	\$7,959,599.67	\$693,896.02
CANH	CANH-HUM6	322: Opioids	5	8	\$0.00	\$955.32	\$0.00
CANH	CANH-HUM6	323: Opioids	16,807	83,220	\$1,704,128.27	\$2,267,344.05	\$1,704,429.61
CANH	CANH-HUM6	327: Opioids	22	36	\$0.00	\$7,486.62	\$0.00
CANH	CANH-HUM6	329: Opioids	1,451	25,769	\$1,041,228.28	\$12,061,392.99	\$1,041,816.04
CANH	CANH-HUM6	343: Farxiga	15	92	\$65,954.23	\$66,267.16	\$65,954.23
CANH	CANH-HUM6	344: Farxiga	2	14	\$260.79	\$568.48	\$260.79
CANH	CANH-HUM6	345: Farxiga	9	154	\$3,344.95	\$60,432.65	\$3,344.95
CANH	CANH-HUM6	347: Farxiga	854	5,544	\$3,113,859.98	\$3,224,561.79	\$3,113,859.98
CANH	CANH-HUM6	348: Farxiga	318	7,447	\$571,751.26	\$5,431,183.35	\$571,967.42
CANH	CANH-HUM6	350: Farxiga	157	3,588	\$699,051.71	\$5,121,664.81	\$699,051.71
CANH	CANH-HUM6	355: Invokana	7	57	\$34,639.80	\$34,908.84	\$34,639.80
CANH	CANH-HUM6	357: Invokana	5	131	\$13,633.78	\$63,237.47	\$13,633.78
CANH	CANH-HUM6	359: Invokana	465	5,409	\$2,881,144.69	\$2,994,752.91	\$2,881,144.69
CANH	CANH-HUM6	360: Invokana	217	5,644	\$406,886.75	\$2,907,034.53	\$407,148.19
CANH	CANH-HUM6	367: Proton Pump	390	1,397	\$294,274.51	\$316,769.84	\$294,274.51
CANH	CANH-HUM6	368: Proton Pump	230	8,974	\$1,460,617.70	\$16,259,894.75	\$1,460,617.70
CANH	CANH-HUM6	369: Proton Pump	51	804	\$250,862.70	\$3,149,913.56	\$250,862.70
CANH	CANH-HUM6	371: Proton Pump	1,148	4,372	\$885,552.76	\$937,181.05	\$885,552.76
CANH	CANH-HUM6	372: Proton Pump	45	551	\$25,592.26	\$813,840.37	\$25,592.26
CANH	CANH-HUM6	379: Valsartan NDC	33	274	\$9,412.53	\$9,485.13	\$9,412.53
CANH	CANH-HUM6	380: Valsartan NDC	27	2,523	\$245,499.70	\$2,187,943.83	\$254,775.78
CANH	CANH-HUM6	381: Valsartan NDC	13	420	\$104,651.43	\$401,148.43	\$104,651.43
CANH	CANH-HUM6	383: Valsartan NDC	1,788	13,357	\$477,999.12	\$493,869.72	\$478,000.12
CANH	CANH-HUM6	391: Benicar	7	194	\$40,123.69	\$43,509.27	\$40,123.69
CANH	CANH-HUM6	392: Benicar	7	79	\$3,131.87	\$38,312.29	\$3,131.87
CANH	CANH-HUM6	393: Benicar	2	67	\$430.97	\$2,413.41	\$430.97
CANH	CANH-HUM6	395: Benicar	4	20	\$5,202.53	\$5,361.48	\$5,202.53
CANH	CANH-HUM6	396: Benicar	2	39	\$365.51	\$2,184.63	\$365.51
CANH	CANH-HUM6	399: Benicar	38,308	1,145,609	\$94,118,750.54	\$906,988,111.13	\$94,151,629.06
CANH	CANH-HUM6	404: Testosterone	1,401	27,559	\$3,151,744.44	\$34,061,495.85	\$3,151,744.46
CANH	CANH-HUM6	405: Testosterone	4	48	\$12,210.60	\$65,239.29	\$12,210.60

HMO (V5.6) Distribution (Funnels and/or Layers)
MSP Client: SMCR-SMCR-3
MSP CRD Batch: All
Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6	
Grand Total	Total	Total	24,874	1,321,417	\$159,022,329.22	\$913,598,456.88	\$161,936,456.80	
SMCR	SMCR-SMCR-3	1: 1.2 P&C Accidents-F63	206	961	\$59,094.58	\$202,523.77	\$67,208.81	
SMCR	SMCR-SMCR-3	2: 1.1 P&C Accidents-F64	44	234	\$76,871.42	\$193,013.87	\$77,430.63	
SMCR	SMCR-SMCR-3	3: 1.5 P&C Accidents-F18	5,702	34,727	\$3,188,644.30	\$13,892,860.23	\$3,269,858.79	
SMCR	SMCR-SMCR-3	4: 1.4 P&C Accidents-F19	1,242	17,015	\$3,296,060.94	\$25,610,135.25	\$3,369,287.01	
SMCR	SMCR-SMCR-3	5: 1.3 P&C Accidents-F62	16,882	444,292	\$50,569,704.80	\$290,740,331.21	\$51,999,425.75	
SMCR	SMCR-SMCR-3	6: 1.7 P&C Accidents-F16	1,647	22,520	\$1,537,764.70	\$13,303,637.59	\$1,563,590.71	
SMCR	SMCR-SMCR-3	7: 1.6 P&C Accidents-F17	19,840	232,870	\$22,241,757.28	\$134,135,673.00	\$22,933,844.57	
SMCR	SMCR-SMCR-3	8: 9.1 NDC Prograf-F40	99	865	\$80,113.05	\$503,167.65	\$80,114.53	
SMCR	SMCR-SMCR-3	12: 11.1 EpiPen-F79	148	299	\$42,123.66	\$108,725.25	\$42,123.66	
SMCR	SMCR-SMCR-3	13: 12.1 Generic Pharma-F92	45	89	\$14,109.30	\$37,061.13	\$14,109.30	
SMCR	SMCR-SMCR-3	14: 12.2 Generic Pharma-F91	89	502	\$3,258.76	\$30,771.33	\$3,258.76	
SMCR	SMCR-SMCR-3	15: 12.3 Generic Pharma-F90	1,747	12,874	\$176,101.54	\$1,986,902.36	\$176,101.54	
SMCR	SMCR-SMCR-3	16: 12.4 Generic Pharma-F89	3	22	\$7,109.17	\$26,307.03	\$7,109.17	
SMCR	SMCR-SMCR-3	17: 12.5 Generic Pharma-F88	102	228	\$4,607.86	\$46,868.57	\$4,611.06	
SMCR	SMCR-SMCR-3	18: 12.6 Generic Pharma-F87	62	113	\$7,604.73	\$30,061.70	\$7,604.73	
SMCR	SMCR-SMCR-3	19: 12.7 Generic Pharma-F86	4,838	32,424	\$693,277.29	\$1,098,407.83	\$693,279.45	
SMCR	SMCR-SMCR-3	20: 12.8 Generic Pharma-F85	40	120	\$243.82	\$6,539.99	\$243.82	
SMCR	SMCR-SMCR-3	21: 12.9 Generic Pharma-F80	345	2,767	\$67,664.05	\$330,944.51	\$67,664.05	
SMCR	SMCR-SMCR-3	22: 12.10 Generic Pharma-F72	6	25	\$2,969.23	\$5,440.54	\$2,969.23	
SMCR	SMCR-SMCR-3	23: 12.11 Generic Pharma-F68	335	2,022	\$15,342.36	\$95,727.17	\$15,342.36	
SMCR	SMCR-SMCR-3	24: 12.12 Generic Pharma-F67	195	439	\$13,134.27	\$64,168.33	\$13,134.27	
SMCR	SMCR-SMCR-3	26: 14.1 Insulin-F96	68	544	\$413,542.44	\$686,431.86	\$413,542.44	
SMCR	SMCR-SMCR-3	27: 14.2 Insulin-F95	1,076	10,795	\$4,142,132.03	\$6,919,750.84	\$4,142,132.03	
SMCR	SMCR-SMCR-3	28: 14.3 Insulin-F94	42	196	\$69,816.17	\$141,135.59	\$69,816.17	
SMCR	SMCR-SMCR-3	29: 14.4 Insulin-F71	166	618	\$205,144.19	\$527,709.04	\$205,144.19	
SMCR	SMCR-SMCR-3	30: 14.5 Insulin-F70	11	28	\$5,694.27	\$14,772.92	\$5,694.27	
SMCR	SMCR-SMCR-3	31: 14.6 Insulin-F69	768	7,314	\$3,718,403.13	\$5,982,188.87	\$3,718,403.13	
SMCR	SMCR-SMCR-3	32: 15.1 Aggrenox-F25	107	169	\$2,045.72	\$12,497.61	\$2,045.72	
SMCR	SMCR-SMCR-3	33: 16.1 NDC Androgel-F27	133	1,334	\$130,794.91	\$420,020.52	\$130,796.35	
SMCR	SMCR-SMCR-3	40: 19.1 DOJ Kickbacks Warn. Chil.-F162	1	1	\$0.00	\$493.99	\$0.00	
SMCR	SMCR-SMCR-3	43: 21.1 Celgene-F97		17	\$2,300,501.94	\$3,754,642.32	\$2,300,501.94	
SMCR	SMCR-SMCR-3	45: 22.1 Glucose Test Strips-F145	2,373	11,428	\$1,364,415.33	\$1,964,447.01	\$1,364,415.33	
SMCR	SMCR-SMCR-3	46: 23.1 Namenda-F165		2	\$0.00	\$1,106.34	\$0.00	
SMCR	SMCR-SMCR-3	47: 24.1 Lidoderm-F193	152	575	\$28,181.64	\$194,991.95	\$28,181.64	
SMCR	SMCR-SMCR-3	48: 24.2 Lidoderm-F192	1	13	\$10,139.61	\$12,533.24	\$10,139.61	
SMCR	SMCR-SMCR-3	49: Clobetasol-F62	537	1,259	\$49,200.39	\$337,606.15	\$49,200.39	
SMCR	SMCR-SMCR-3	50: Baclofen-F152	289	1,559	\$22,056.66	\$295,179.13	\$22,058.40	
SMCR	SMCR-SMCR-3	51: Benazepril-F153	258	2,137	\$22,124.66	\$107,011.43	\$22,124.66	
SMCR	SMCR-SMCR-3	52: Digoxin-F154	236	1,449	\$17,965.71	\$120,823.02	\$17,965.71	
SMCR	SMCR-SMCR-3	53: Divalproex-F155	91	881	\$29,970.48	\$289,658.11	\$29,970.48	
SMCR	SMCR-SMCR-3	54: Ursodiol-F156		33	\$21,979.47	\$122,231.35	\$21,979.47	
SMCR	SMCR-SMCR-3	55: Aggrenox 2 NDC Brand-F265		1	\$3,776.64	\$5,257.63	\$3,776.64	
SMCR	SMCR-SMCR-3	56: Aggrenox 2 NDC Generic-F266	14	84	\$24,590.76	\$79,472.19	\$24,590.76	
SMCR	SMCR-SMCR-3	57: HP Acthar-F66	2	22	\$758,775.09	\$1,021,404.80	\$758,775.09	
SMCR	SMCR-SMCR-3	58: Lipitor Pfizer-F75		5	\$30,551.68	\$65,606.12	\$30,551.68	
SMCR	SMCR-SMCR-3	60: Restasis	236	1,150	\$702,868.15	\$1,025,323.25	\$702,868.15	
SMCR	SMCR-SMCR-3	62: Humira NDC Brand	41	532	\$1,971,199.10	\$3,830,822.77	\$1,971,199.10	
SMCR	SMCR-SMCR-3	63: Evzio NDC		1	\$0.00	\$9,845.00	\$0.00	
SMCR	SMCR-SMCR-3	65: 2.Hip Replacement-192	7	12	\$20,469.75	\$65,376.05	\$22,660.62	
SMCR	SMCR-SMCR-3	66: 2.Hip Replacement-193	11	21	\$20,940.69	\$110,504.50	\$29,096.73	
SMCR	SMCR-SMCR-3	67: 2.Hip Replacement-194	11	323	\$64,437.93	\$773,345.40	\$64,639.23	
SMCR	SMCR-SMCR-3	68: 2.Hip Replacement-195	4	29	\$1,609.22	\$13,737.52	\$1,609.22	
SMCR	SMCR-SMCR-3	70: 2.Hip Replacement-197	3	9	\$1,472.76	\$5,179.25	\$1,472.76	
SMCR	SMCR-SMCR-3	73: 2.Hip Replacement-200	12	181	\$53,714.64	\$118,642.82	\$53,830.43	
SMCR	SMCR-SMCR-3	74: 2.Hip Replacement-201	10	39	\$2,005.39	\$8,329.05	\$2,005.39	
SMCR	SMCR-SMCR-3	76: 2.Hip Replacement-203		8	\$6,463.47	\$8,677.55	\$6,463.47	
SMCR	SMCR-SMCR-3	79: 2.Hip Replacement-207		2	\$172.90	\$840.00	\$172.90	
SMCR	SMCR-SMCR-3	80: 2.Hip Replacement-208		1	\$397.10	\$2,411.00	\$397.10	
SMCR	SMCR-SMCR-3	101: 2.Hip Replacement-230	16	37	\$59,390.22	\$210,118.00	\$67,546.26	
SMCR	SMCR-SMCR-3	102: 2.Hip Replacement-231	16	314	\$60,317.39	\$231,498.40	\$60,557.15	
SMCR	SMCR-SMCR-3	103: 2.Hip Replacement-232		10	\$59,622.78	\$418,404.50	\$59,734.22	
SMCR	SMCR-SMCR-3	105: 2.Hip Replacement-235	4	12	\$620.55	\$4,879.25	\$620.55	
SMCR	SMCR-SMCR-3	108: 2.Hip Replacement-238	19	157	\$34,882.62	\$111,262.45	\$34,905.95	
SMCR	SMCR-SMCR-3	109: 2.Hip Replacement-239	16	175	\$13,381.92	\$78,027.03	\$13,477.05	
SMCR	SMCR-SMCR-3	111: 2.Hip Replacement-241	13	43	\$2,102.33	\$8,999.55	\$2,102.33	
SMCR	SMCR-SMCR-3	117: 3.Pelvic Mesh-536		1	\$0.00	\$472.00	\$0.00	
SMCR	SMCR-SMCR-3	118: 3.Pelvic Mesh-537		1	\$352.41	\$1,677.00	\$352.41	
SMCR	SMCR-SMCR-3	120: 3.Pelvic Mesh-539		1	25	\$5,075.87	\$37,390.00	\$5,075.87
SMCR	SMCR-SMCR-3	123: 3.Pelvic Mesh-542	5	10	\$6,265.26	\$26,943.00	\$7,972.01	
SMCR	SMCR-SMCR-3	126: 3.Pelvic Mesh-546	11	76	\$1,739.04	\$14,836.73	\$1,960.90	
SMCR	SMCR-SMCR-3	127: 3.Pelvic Mesh-547		1	\$0.00	\$8,807.00	\$0.00	
SMCR	SMCR-SMCR-3	132: 3.Pelvic Mesh-552		1	14	\$1,020.73	\$2,828.00	\$1,020.73
SMCR	SMCR-SMCR-3	151: 3.Pelvic Mesh-571	49	106	\$76,112.78	\$336,484.37	\$80,001.30	
SMCR	SMCR-SMCR-3	153: 3.Pelvic Mesh-573	49	2,253	\$282,874.55	\$2,175,804.70	\$297,719.82	
SMCR	SMCR-SMCR-3	155: 3.Pelvic Mesh-579	76	468	\$28,261.81	\$147,418.23	\$29,562.47	
SMCR	SMCR-SMCR-3	156: 3.Pelvic Mesh-580		2	\$297.39	\$19,307.36	\$297.39	
SMCR	SMCR-SMCR-3	169: 4.Granuflo-282		589	8,339	\$816,903.51	\$8,617,286.90	\$826,724.69

HMO (V5.6) Distribution (Funnels and/or Layers)
MSP Client: SMCR-SMCR-3
MSP CRD Batch: All
Date of Issue: March 15, 2023

Client Abreviation	Msp Client Updated	V5.6 Label	Unique Members V5.6	Claims V5.6	Paid Amount V5.6	Bill Amount V5.6	Paid Adjusted V5.6
Grand Total	Total	Total	24,874	1,321,417	\$159,022,329.22	\$913,598,456.88	\$161,936,456.80
SMCR	SMCR-SMCR-3	171: 4.Granuflo-284	110	1,067	\$216,411.95	\$1,752,810.03	\$221,435.64
SMCR	SMCR-SMCR-3	173: 4.Granuflo-286	25	1,313	\$290,663.44	\$4,411,009.08	\$290,663.44
SMCR	SMCR-SMCR-3	209: 5.IVC Filter-347	197	9,282	\$1,818,606.75	\$15,691,893.12	\$1,826,463.24
SMCR	SMCR-SMCR-3	210: 6.Incretin-131	34	283	\$160,106.21	\$245,123.98	\$160,106.21
SMCR	SMCR-SMCR-3	211: 6.Incretin-132	32	2,030	\$427,762.96	\$2,478,906.59	\$429,069.59
SMCR	SMCR-SMCR-3	212: 6.Incretin-133	83	2,746	\$345,810.83	\$2,390,944.45	\$349,452.53
SMCR	SMCR-SMCR-3	214: 6.Incretin-135	2	57	\$8,085.26	\$53,878.61	\$8,209.89
SMCR	SMCR-SMCR-3	215: 6.Incretin-136	5	70	\$12,298.83	\$65,628.39	\$12,298.83
SMCR	SMCR-SMCR-3	216: 6.Incretin-137	1,023	10,226	\$6,884,601.97	\$10,502,657.69	\$6,884,601.97
SMCR	SMCR-SMCR-3	218: 6.Incretin-139	905	20,540	\$1,912,538.40	\$12,346,882.90	\$1,953,234.37
SMCR	SMCR-SMCR-3	229: 7.Taxotere-406	243	1,383	\$40,436.73	\$179,831.09	\$41,355.39
SMCR	SMCR-SMCR-3	234: 8.Meso/Asbestos-143	85	747	\$144,618.96	\$1,217,628.46	\$145,179.76
SMCR	SMCR-SMCR-3	235: 8.Meso/Asbestos-144	25	923	\$139,144.20	\$1,055,080.56	\$152,078.56
SMCR	SMCR-SMCR-3	237: 8.Meso/Asbestos-146	4	28	\$21,527.02	\$117,256.51	\$21,527.02
SMCR	SMCR-SMCR-3	239: 8.Meso/Asbestos-148	2	37	\$1,276.83	\$20,620.82	\$1,276.83
SMCR	SMCR-SMCR-3	245: 8.Meso/Asbestos-154	42	211	\$45,376.99	\$775,977.48	\$47,822.73
SMCR	SMCR-SMCR-3	306: Fluoroquinolone	578	9,812	\$1,905,418.44	\$14,439,537.08	\$1,934,431.89
SMCR	SMCR-SMCR-3	307: Fluoroquinolone	148	3,599	\$1,298,582.61	\$11,447,523.23	\$1,317,111.14
SMCR	SMCR-SMCR-3	310: Fluoroquinolone	1,174	21,878	\$6,306,785.15	\$49,711,384.08	\$6,348,995.72
SMCR	SMCR-SMCR-3	317: Opioids	592	9,820	\$376,580.69	\$1,373,557.62	\$376,583.35
SMCR	SMCR-SMCR-3	318: Opioids	341	4,181	\$538,275.23	\$3,707,263.14	\$542,497.68
SMCR	SMCR-SMCR-3	319: Opioids	2	2	\$0.00	\$207.29	\$0.00
SMCR	SMCR-SMCR-3	321: Opioids	8	71	\$3,078.48	\$13,263.85	\$3,743.09
SMCR	SMCR-SMCR-3	323: Opioids	7,810	45,359	\$1,185,650.93	\$4,801,688.92	\$1,185,669.35
SMCR	SMCR-SMCR-3	327: Opioids	7	11	\$0.00	\$2,410.97	\$0.00
SMCR	SMCR-SMCR-3	329: Opioids	32	442	\$38,244.36	\$329,027.92	\$38,464.57
SMCR	SMCR-SMCR-3	344: Farxiga	1	3	\$261.14	\$689.00	\$261.14
SMCR	SMCR-SMCR-3	345: Farxiga	2	33	\$832.23	\$14,951.30	\$832.23
SMCR	SMCR-SMCR-3	347: Farxiga	125	405	\$247,023.57	\$395,354.06	\$247,023.57
SMCR	SMCR-SMCR-3	348: Farxiga	57	1,023	\$94,790.13	\$549,829.26	\$96,545.16
SMCR	SMCR-SMCR-3	350: Farxiga	16	174	\$80,303.24	\$308,780.28	\$80,784.97
SMCR	SMCR-SMCR-3	357: Invokana	5	200	\$23,055.54	\$226,949.26	\$23,150.67
SMCR	SMCR-SMCR-3	359: Invokana	99	944	\$522,642.88	\$795,966.78	\$522,642.88
SMCR	SMCR-SMCR-3	360: Invokana	88	2,061	\$318,532.28	\$1,386,007.75	\$321,952.80
SMCR	SMCR-SMCR-3	367: Proton Pump	50	414	\$99,526.09	\$179,005.33	\$99,526.09
SMCR	SMCR-SMCR-3	368: Proton Pump	808	41,364	\$4,953,812.80	\$42,379,688.34	\$4,981,937.01
SMCR	SMCR-SMCR-3	369: Proton Pump	220	3,927	\$1,505,164.99	\$9,287,673.98	\$1,510,854.05
SMCR	SMCR-SMCR-3	371: Proton Pump	82	631	\$201,959.70	\$318,629.41	\$201,959.70
SMCR	SMCR-SMCR-3	372: Proton Pump	91	1,675	\$580,937.94	\$4,662,137.53	\$581,628.46
SMCR	SMCR-SMCR-3	379: Valsartan NDC	11	90	\$1,051.60	\$20,209.90	\$1,051.60
SMCR	SMCR-SMCR-3	380: Valsartan NDC	33	1,961	\$206,591.84	\$1,768,224.86	\$208,224.34
SMCR	SMCR-SMCR-3	381: Valsartan NDC	26	360	\$62,441.77	\$686,292.76	\$62,902.02
SMCR	SMCR-SMCR-3	383: Valsartan NDC	485	3,630	\$51,368.96	\$1,053,807.37	\$51,399.74
SMCR	SMCR-SMCR-3	391: Benicar	9	38	\$11,227.13	\$26,019.93	\$11,227.13
SMCR	SMCR-SMCR-3	392: Benicar	261	4,307	\$698,818.29	\$4,575,168.08	\$702,823.23
SMCR	SMCR-SMCR-3	393: Benicar	246	3,589	\$149,401.16	\$961,985.28	\$154,141.39
SMCR	SMCR-SMCR-3	395: Benicar	3	7	\$802.65	\$3,621.67	\$802.65
SMCR	SMCR-SMCR-3	396: Benicar	34	540	\$21,435.08	\$152,601.46	\$21,992.12
SMCR	SMCR-SMCR-3	399: Benicar	11,724	244,179	\$24,966,957.66	\$178,605,641.16	\$25,295,054.57
SMCR	SMCR-SMCR-3	404: Testosterone	152	2,879	\$337,175.04	\$2,155,509.36	\$339,302.02

Exhibit

	Client Company Name	Msp Client Updated	Designated Series	MSP Entity	Ownership %	Client State	Client Type	Min DOS Updated	Max DOS Updated	Paid Amount V5.6 (100% Basis, (close 12/31/2022)	CCRA Interest	Assignors' Interest	Total
New Claims													
	Avmed, Inc.	AVDI-AVDI-2	MSP Recovery Claims, Series LLC	Series-17-03-615	100%	FL	HMO	27/06/2019	24/12/2020	\$69,604,911.21	\$ 34,802,455.61	\$ 34,802,455.61	\$69,604,911.21
	Avmed, Inc.	AVDI-AVDI3-2	MSP Recovery Claims, Series LLC	Series-17-03-615	100%	FL	HMO	27/06/2019	30/06/2021	\$80,993,596.54	\$ 40,496,798.27	\$ 40,496,798.27	\$80,993,596.54
	Cano Health, LLC	CANH-HUM6	MSP Recovery Claims, Series LLC	Series-17-03-569	100%	FL	MSO	01/01/2018	19/05/2022	\$549,236,260.17	\$ 274,618,130.09	\$ 274,618,130.09	\$549,236,260.17
	Summacare, Inc.	SMCR-SMCR-3	MSP Recovery Claims, Series LLC	Series 16-11-509	100%	OH	HMO	25/03/2019	30/06/2021	\$159,022,329.22	\$ 79,511,164.61	\$ 79,511,164.61	\$159,022,329.22
										\$858,857,097.14	\$429,428,548.57	\$429,428,548.57	\$858,857,097.14

Schedule 1.1(a)
Acquired Companies

Series 21-12-1644, a designated series of MSP Recovery Claims, Series LLC, a Delaware limited liability Company (“**Series 21-12-1644**”)

Series 23-03-1907, a designated series of MSP Recovery Claims, Series LLC, a Delaware limited liability Company (“**Series 23-03-1907**”)

Series 21-06-1592, a designated series of MSP Recovery Claims, Series LLC, a Delaware limited liability Company (“**Series 21-06-1592**”)

Related CCRAs:

Third Agreement for the Purchase and Assignment of Claims, by and between AvMed, Inc., a Florida corporation and Series 21-12-1644, effective December 28, 2021

Assignment, dated March 26, 2023, by and between Series 17-03-569 and Series 23-03-1907, in connection with certain Claims which were assigned to Series 17-03-569 pursuant to the Amended and Restated Claims Recovery and Assignment Agreement, by and among Cano Health, LLC, a Florida limited liability company, Seller and Series 17-03-569, effective as of December 21, 2021, as amended by the First Amendment to the Amended and Restated Claims Recovery and Assignment Agreement, effective as of September 30, 2022

Third Agreement for the Purchase and Assignment of Claims, by and between SummaCare, Inc., an Ohio corporation and Series 21-06-1592, effective July 23, 2021

Schedule 3.04(a)

Capitalization

Schedule 3.04(a) - Equity Interests of Acquired Companies

Entity	Manager	Member	Equity Interest Ownership
Series 21-12-1644, a designated series of MSP Recovery Claims, Series LLC	MSP Recovery, LLC	MSP Recovery, LLC	100%
Series 23-03-1907, a designated series of MSP Recovery Claims, Series LLC	MSP Recovery, LLC	MSP Recovery, LLC	100%
Series 21-06-1592, a designated series of MSP Recovery Claims, Series LLC	MSP Recovery, LLC	MSP Recovery, LLC	100%